Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:58:49 ON 03 SEP 2008

=> file caplus medline biosis embase
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'CAPLUS' ENTERED AT 09:59:15 ON 03 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:59:15 ON 03 SEP 2008

FILE 'BIOSIS' ENTERED AT 09:59:15 ON 03 SEP 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 09:59:15 ON 03 SEP 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s neuropeptide Y
L1       46771 NEUROPEPTIDE Y

=> s sexual dysfunction
L2       27134 SEXUAL DYSFUNCTION

=> s sexual disorder
L3        6364 SEXUAL DISORDER

=> L2 or L3
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 or L3
L4       31764 L2 OR L3

=> s L1 and L4
L5          85 L1 AND L4

=> dup rem L5
PROCESSING COMPLETED FOR L5
L6           80 DUP REM L5 (5 DUPLICATES REMOVED)

=> s L6 and (AY<2002 or PY<2002 or PRY<2002)
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
```

```
   2 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
L7          39 L6 AND (AY<2002 OR PY<2002 OR PRY<2002)

=> d 30-39 L7 ibib abs

L7   ANSWER 30 OF 39  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:          2001:338067  CAPLUS
DOCUMENT NUMBER:           134:348236
TITLE:                     Phosphodiesterase inhibitors for the treatment of
                           female sexual arousal dysfunction
INVENTOR(S):               Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S):        Pfizer Limited, UK; Pfizer Inc.
SOURCE:                    Eur. Pat. Appl., 129 pp.
                           CODEN: EPXXDW
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    5
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     EP 1097706           A1    20010509    EP 2000-309718         20001103 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     AT 285249            T     20050115    AT 2000-309722         20001103 <--
     PT 1097719           T     20050429    PT 2000-309722         20001103 <--
     ES 2233297           T3    20050616    ES 2000-309722         20001103 <--
     ZA 2000006374        A     20020506    ZA 2000-6374           20001106 <--
     ZA 2000006375        A     20020506    ZA 2000-6375           20001106 <--
     ZA 2000006376        A     20020506    ZA 2000-6376           20001106 <--
     ZA 2000006378        A     20020506    ZA 2000-6378           20001106 <--
     AU 781186            B2    20050512    AU 2000-71411          20001106 <--
     AU 781400            B2    20050519    AU 2000-71407          20001106 <--
     AU 781403            B2    20050519    AU 2000-71408          20001106 <--
     CA 2323183           A1    20010508    CA 2000-2323183        20001107 <--
     CA 2323191           A1    20010508    CA 2000-2323191        20001107 <--
     CA 2323464           A1    20010508    CA 2000-2323464        20001107 <--
     CA 2324484           A1    20010508    CA 2000-2324484        20001107 <--
     NO 2000005618        A     20010509    NO 2000-5618           20001107 <--
     NO 2000005661        A     20010509    NO 2000-5661           20001107 <--
     NO 2000005662        A     20010509    NO 2000-5662           20001107 <--
     HU 2000004347        A2    20010628    HU 2000-4347           20001107 <--
     HU 2000004348        A2    20010628    HU 2000-4348           20001107 <--
     HU 2000004349        A2    20010628    HU 2000-4349           20001107 <--
     HU 2000004350        A2    20010628    HU 2000-4350           20001107 <--
     CN 1320426           A     20011107    CN 2000-137665         20001107 <--
     CN 1322526           A     20011121    CN 2000-137671         20001107 <--
     CN 1328824           A     20020102    CN 2000-137670         20001107 <--
     NZ 508006            A     20020628    NZ 2000-508006         20001107 <--
     NZ 508007            A     20020628    NZ 2000-508007         20001107 <--
     NZ 508011            A     20020628    NZ 2000-508011         20001107 <--
     NZ 508012            A     20020628    NZ 2000-508012         20001107 <--
     BR 2000005266        A     20030408    BR 2000-5266           20001107 <--
     CN 1575816           A     20050209    CN 2004-10071390       20001107 <--
     CN 1636597           A     20050713    CN 2004-10085955       20001107 <--
     JP 2001206855        A     20010731    JP 2000-339905         20001108 <--
     JP 2001213802        A     20010807    JP 2000-339853         20001108 <--
     JP 2001247478        A     20010911    JP 2000-339949         20001108 <--
```

JP 2001247479	A	20010911	JP 2000-339957	20001108	<--
BR 2000005276	A	20030408	BR 2000-5276	20001108	<--
BR 2000005299	A	20030415	BR 2000-5299	20001108	<--
US 6734186	B1	20040511	US 2000-708392	20001108	<--
US 20040254153	A1	20041216	US 2003-686390	20031015	<--
US 20050020547	A1	20050127	US 2003-686282	20031015	<--
US 20050070499	A1	20050331	US 2003-686349	20031015	<--
IN 2004DE00033	A	20070504	IN 2004-DE33	20040107	<--
KR 2004074021	A	20040821	KR 2004-50971	20040701	<--
KR 2004074022	A	20040821	KR 2004-50972	20040701	<--
KR 2004074023	A	20040821	KR 2004-50973	20040701	<--
JP 2005013237	A	20050120	JP 2004-268608	20040915	<--
JP 2005021167	A	20050127	JP 2004-267669	20040915	<--
JP 2005043377	A	20050217	JP 2004-269807	20040916	<--
JP 2005070055	A	20050317	JP 2004-269732	20040916	<--
AU 2005201482	A1	20050505	AU 2005-201482	20050407	<--
AU 2005202166	A1	20050616	AU 2005-202166	20050518	<--
AU 2005202750	A1	20050721	AU 2005-202750	20050623	<--
JP 2005350482	A	20051222	JP 2005-233224	20050811	<--
PRIORITY APPLN. INFO.:			GB 1999-26437	A 19991108	<--
			GB 2000-4021	A 20000218	<--
			GB 2000-13001	A 20000526	<--
			GB 2000-16563	A 20000705	<--
			GB 2000-17141	A 20000712	<--
			US 2000-175161P	P 20000107	<--
			US 2000-192962P	P 20000329	<--
			US 2000-217479P	P 20000711	<--
			US 2000-221014P	P 20000727	<--
			US 2000-221093P	P 20000727	<--
			AU 2000-71408	A3 20001106	<--
			CN 2000-137670	A3 20001107	<--
			KR 2000-65740	A3 20001107	<--
			KR 2000-65863	A3 20001107	<--
			KR 2000-65868	A3 20001107	<--
			JP 2000-339853	A3 20001108	<--
			JP 2000-339905	A3 20001108	<--
			JP 2000-339949	A3 20001108	<--
			JP 2000-339957	A3 20001108	<--
			US 2000-708392	A3 20001108	<--

AB A method of treating a female suffering from female sexual dysfunction (FSD), in particular female sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. Said agent is a phosphodiesterase (PDE) inhibitor wherein said PDE is a cAMP hydrolyzing PDE (and optionally cGMP hydroyzing).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:880962 CAPLUS

DOCUMENT NUMBER: 134:42445

TITLE: Preparation of piperidine amino acid derivatives as melanocortin-4 receptor agonists

INVENTOR(S): Bakshi, Raman K.; Barakat, Khaled J.; Nargund, Ravi P.; Palucki, Brenda L.; Patchett, Arthur A.; Sebhat, Iyassu; Ye, Zhixiong; Van, Der Ploeg Leonardus H. T.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Van Der Ploeg, Leonardus H. T.

SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2000074679	A1	20001214	WO 2000-US14930	20000531	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2377369	A1	20001214	CA 2000-2377369	20000531	<--
EP 1187614	A1	20020320	EP 2000-937961	20000531	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2003505435	T	20030212	JP 2001-512328	20000531	<--
AU 766191	B2	20031009	AU 2000-53068	20000531	<--
US 6350760	B1	20020226	US 2000-585111	20000601	<--
US 20020137664	A1	20020926	US 2001-990499	20011121	<--
AU 2003248456	A1	20031106	AU 2003-248456	20030929	<--

PRIORITY APPLN. INFO.:	US 1999-137477P	P	19990604 <--
	US 1999-169209P	P	19991202 <--
	WO 2000-US14930	W	20000531 <--
	US 2000-585111	A3	20000601 <--

OTHER SOURCE(S): MARPAT 134:42445
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Piperidine derivs. I [R2C2 = aryl, 5- or 6-membered heteroaryl or heterocyclyl, 5- to 7-membered carbocyclyl, which may be substituted; L = (CRb2)m, where Rb = H, alkyl, (CH2)n-cycloalkyl or -aryl; m = 0-2, n = 0-3; X, Y = (CH2)0-2; Ra = H, alkyl, (CHRb)n-cycloalkyl, -aryl, -heteroaryl, -O(CHRb)naryl, which may be substituted; Re = H, alkyl, (CH2)n-aryl, -cycloalkyl, -heteroaryl, which may be substituted, acyl, sulfonyl, etc.; R1 = H, alkyl, (CH2)n-cycloalkyl, -aryl, -heteroaryl, -heterocyclyl; R2 = any group given for R1, CN, (CH2)n-carboxamido, -carboxy, -acylamino, sulfonylamino, -amino, etc.] were prepared as agonists of the human melanocortin receptors, in particular, the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Thus, II trifluoroacetate, prepared by coupling of Et 1-(D-4-chlorophenylalanyl)-4-cyclohexyl-4-[(1,2,4-triazol-1-yl)methyl]piperidine trifluoroacetate (preparation given) with N-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Boc-D-Tic), was > 2,200-fold, > 10,000-fold, and > 580-fold selective for the human MC-4R over human MC-1R, MC-2R, and MC-3R, resp.
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:814460 CAPLUS

DOCUMENT NUMBER: 133:350139
TITLE: Preparation of 3a,4,5,9b-tetrahydro-1H-benzo[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and disorders of CNS
INVENTOR(S): Dax, Scott; Mcnally, James
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000068197	A1	20001116	WO 2000-US10981	20000420 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373035	A1	20001116	CA 2000-2373035	20000420 <--
EP 1177172	A1	20020206	EP 2000-928340	20000420 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6841552	B1	20050111	US 2000-552969	20000420 <--
TW 553933	B	20030921	TW 2000-89108583	20000703 <--
MX 2001PA11321	A	20030801	MX 2001-PA11321	20011105 <--
US 20050054709	A1	20050310	US 2004-900554	20040728 <--
US 6987188	B2	20060117		

PRIORITY APPLN. INFO.:	US 1999-132660P	P	19990505 <--
	US 2000-552969	A	20000420 <--
	WO 2000-US10981	W	20000420 <--

OTHER SOURCE(S): MARPAT 133:350139
GI



I



II

AB Title compds. [I; X = NR2YLZ, NH; X1 = CH2, CO; dotted bonds = single, double; R1 = H, OH, Cl, F, I, Br, alkyl alkoxy, (un)substituted phenyl; R3 = alkyl, cycloalkyl, naphthyl, heteroaryl, (un)substituted phenyl; n = 0, 1, 2; R2 = H, alkyl; Y = CH2, CO; L = alkylene, cycloalkylene, arylclkylene, (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl, (N-methylene)piperidin-4,4-diyl; Z = (un)substituted Ph, N-sulfonamido, N-(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl], enantiomers, diastereomers, and pharmaceutically acceptable salts are prepared as such are useful in the treatment of obesity, eating disorders, anorexia nervosa, bulimia nervosa, diabetes, hypertension, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual/reproductive disorders, depression or anxiety and disorders of the central nervous system. Pharmaceutical composition comprising therapeutically effective amount of title compds. and pharmaceutically acceptable carrier and method of treating disorders and diseases associated with NPY receptor subtype Y5 comprising administering to a mammal are claimed. Thus, the title compound II was prepared and tested for the human NPY Y5 receptor binding affinity.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:772615 CAPLUS

DOCUMENT NUMBER: 133:335247

TITLE: Preparation of triazinamines, thiazolamines, and benzo[2,3]thiepino[4,5-d][1,3]thiazol-2-ylamines as selective NPY (Y5) antagonists

INVENTOR(S): Marzabadi, Mohammad R.; Wong, Wai C.; Noble, Stewart A.; Desai, Mahesh N.

PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA

SOURCE: PCT Int. Appl., 291 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064880	A1	20001102	WO 2000-US10784	20000421 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6340683	B1	20020122	US 1999-296332	19990422 <--
US 6124331	A	20000926	US 1999-343994	19990630 <--
US 6218408	B1	20010417	US 1999-343762	19990630 <--
CA 2371274	A1	20001102	CA 2000-2371274	20000421 <--
EP 1183245	A1	20020306	EP 2000-923566	20000421 <--
EP 1183245	B1	20070509		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2002543067	T	20021217	JP 2000-613833	20000421 <--
AU 775166	B2	20040722	AU 2000-43667	20000421 <--
US 20020103201	A1	20020801	US 2002-37859	20020103 <--
US 6569856	B2	20030527		
US 6989379	B1	20060124	US 2002-9849	20020411 <--
US 20040019050	A1	20040129	US 2003-420238	20030422 <--
AU 2004222792	A1	20041118	AU 2004-222792	20041021 <--
AU 2004222792	B2	20071122		
US 20050176709	A1	20050811	US 2005-99960	20050406 <--
US 7189720	B2	20070313		
US 20080045524	A1	20080221	US 2007-716925	20070312 <--

PRIORITY APPLN. INFO.:		
US 1999-296332	A2	19990422 <--
US 1999-343762	A2	19990630 <--
US 1999-343994	A2	19990630 <--
WO 2000-US10784	W	20000421 <--
US 2002-37859	A1	20020103
US 2002-9849	A1	20020411
US 2005-99960	A1	20050406

OTHER SOURCE(S): MARPAT 133:335247
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. (I), (II), and (III) [wherein R1 = halo, NR3R4, or (un)substituted Ph or heteroaryl; R2 = NR3R4; R3 and R4 = independently H, hydroxyalkyl, thioalkyl, alkoxyalkyl, alkylthioalkyl, (thio)carbamoylalkyl, carboxyalkyl, aminoalkyl, cyanoalkyl, (thio)acyl, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, or (un)substituted phenyl(alkyl) or heteroarylalkyl; or R3 and R4 taken together with the N to which they are attached = (un)substituted azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, (thio)morpholinyl, oxazepanyl, thiazepanyl, piperazinyl, or diazepanyl; R5 = substituted amino(alkyl)cyclohexyl(alkyl)amino, amino(alkyl)piperidinyl, piperidinyl(alkyl)amino, piperazinyl, etc.; Y = O,S, or NH; Ar = (un)substituted heteroaryl; R6 = H, alkyl, hydroxyalkyl, alkoxyalkyl, or (un)substituted Ph; R7 = substituted aminoalkylamino or amino(alkyl)cyclohexyl(alkyl)amino; B = O, NH, or S; X = S, S(O), or SO2; R8 = H or alkyl; R9 = H, halo, CN, OH, NO2, amino, sulfo, hydroxyalkyl, alkoxyalkyl, carbamoylalkyl, alkylaminoalkyl, polyfluoroalkyl, or (amino)alkyl; m = 0-1; n = 1-2] were prepared as selective antagonists for

the neurotransmitter neuropeptide Y (Y5) receptor. For example, reaction of N-[[4-(aminomethyl)cyclohexyl]methyl]-1-naphthalenesulfonamide with 2,4-dichloro-6-(isopropylamino)triazine afforded the triazinediamine (IV) in 60% yield. Assays of IV against cloned human NPY receptors showed selectivity for NPY (Y5) with a Ki of 138 nM compared to values of > 100,000 nM for NPY (Y1), (Y2), and (Y4). The functional in vitro activity for IV, characterized using a RIA of cAMP, was also determined (pKb = 6.0). I are useful for the treatment of obesity, bulimia nervosa, sexual/reproductive disorders, depression, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, sleep disturbances, or any condition in which antagonism of the Y5 receptor may be beneficial.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 34 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:741026 CAPLUS
DOCUMENT NUMBER: 133:309895
TITLE: Aminotriazole compounds useful as neuropeptide Y receptor ligands, process for their preparation, and pharmaceutical compositions containing them
INVENTOR(S): Fauchere, Jean-Luc; Ortuno, Jean-Claude; Duhault, Jacques; Boutin, Jean Albert; Levens, Nigel
PATENT ASSIGNEE(S): Adir et Compagnie, Fr.
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1044970	A1	20001018	EP 2000-401039	20000414	<--
EP 1044970	B1	20030115			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
FR 2792314	A1	20001020	FR 1999-4721	19990415	<--
FR 2792314	B1	20010601			
MX 200003557	A	20020201	MX 2000-3557	20000412	<--
BR 2000001602	A	20010821	BR 2000-1602	20000413	<--
CA 2305940	A1	20001015	CA 2000-2305940	20000414	<--
NO 2000001964	A	20001016	NO 2000-1964	20000414	<--
NZ 504023	A	20001027	NZ 2000-504023	20000414	<--
ZA 2000001908	A	20001031	ZA 2000-1908	20000414	<--
JP 2000309579	A	20001107	JP 2000-113113	20000414	<--
CN 1272493	A	20001108	CN 2000-106579	20000414	<--
CN 1145616	C	20040414			
HU 2000001562	A2	20010428	HU 2000-1562	20000414	<--
HU 2000001562	A3	20030528			
US 6245916	B1	20010612	US 2000-549745	20000414	<--
AT 231133	T	20030215	AT 2000-401039	20000414	<--
AU 761586	B2	20030605	AU 2000-27765	20000414	<--
ES 2190396	T3	20030801	ES 2000-401039	20000414	<--
US 20010018522	A1	20010830	US 2001-799199	20010305	<--
US 6596749	B2	20030722			
PRIORITY APPLN. INFO.:			FR 1999-4721 A	19990415	<--
			US 2000-549745 A3	20000414	<--

OTHER SOURCE(S): MARPAT 133:309895
GI



AB Title compds. Q-NH-A-CO-NH-(NH)n-W-Z (I) are disclosed [wherein n = 0 or 1; W = CO, S(O)q; q = 0, 1, 2; Q = rings G1-G4; Z = alkyl, (un)substituted aryl, heteroaryl, aralkyl, aralkenyl, etc.; A = A2, A1A2, A2A1, or A1A2A1; A1 = alkylene; A2 = cycloalkylene, (un)substituted phenylene, naphthylene, or heteroarylene; R = H, alkyl, (un)substituted aryl, heteroaryl, aralkyl, etc.; R1 = alkyl, (un)substituted aryl, heteroaryl, aralkyl, etc.]. Approx. 100 compds. I are listed, most with phys. data. I are ligands of neuropeptide Y (NPY) receptors, and as such are useful for treatment of metabolic disorders, including diabetes, obesity, bulimia, and anorexia nervosa, as well as hypertension, anxiety, depression, epilepsy, sexual disorders, and sleep disorders. For instance, 4-[[(tert-butoxycarbonyl)amino]methyl]benzoic acid was amidated with benzenesulfonohydrazide, followed by deprotection of the amine, reaction with benzoyl isothiocyanate, and cyclocondensation with 3-(trifluoromethyl)phenylhydrazine, to give title compound II. This compound had an IC50 of 80 nM for binding to Y5 receptors in vitro. Compds. I also decreased food consumption and weight gain in obese mice.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 35 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:795654 CAPLUS
DOCUMENT NUMBER: 132:22957
TITLE: Preparation of spiropiperidine derivatives as melanocortin receptor agonists
INVENTOR(S): Nargund, Ravi P.; Ye, Zhixiong; Palucki, Brenda L.; Bakshi, Raman K.; Patchett, Arthur A.; Van Der Ploeg, Leonardus H. T.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964002	A1	19991216	WO 1999-US13252	19990610 <--

W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2334551	A1	19991216	CA 1999-2334551	19990610	<--
AU 9946801	A	19991230	AU 1999-46801	19990610	<--
AU 742425	B2	20020103			
EP 1085869	A1	20010328	EP 1999-930220	19990610	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
US 6294534	B1	20010925	US 1999-329814	19990610	<--
JP 2002517444	T	20020618	JP 2000-553071	19990610	<--
US 20010029259	A1	20011011	US 2001-781373	20010212	<--
US 6410548	B2	20020625			

PRIORITY APPLN. INFO.:	US 1998-88908P	P	19980611 <--
	GB 1998-17179	A	19980806 <--
	US 1999-123260P	P	19990308 <--
	US 1999-329814	A3	19990610 <--
	WO 1999-US13252	W	19990610 <--

OTHER SOURCE(S): MARPAT 132:22957

GI



I



AB Certain novel spiropiperidine compds. I [Cy2 = six-membered aromatic ring containing 0 or 1 N; X = O, CH2, etc.; Q = Q1; Y = CO, SO2, etc; R1, Rb = H, C1-8 alkyl, etc.; R2 = H or halo; Rc = Rb, halo, ORb, NHSO2Rb, N(Rb)2, SO2Rb, CF3, OCF3; Cy = aryl, 5 or 6 membered heteroaryl, 5 or 6 membered heterocyclyl, 5 or 6 membered carbocyclyl; m, p, q independently = 0, 1, or 2] are agonists of melanocortin receptors (no data) and are useful for the treatment, control or prevention of diseases and disorders responsive to the activation of melanocortin receptors. The compds. of the present invention are therefore useful for treatment of diseases and disorders

such as obesity, diabetes, sexual dysfunction including erectile dysfunction and female sexual dysfunction.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:801276 CAPLUS
DOCUMENT NUMBER: 123:218491
ORIGINAL REFERENCE NO.: 123:38615a,38618a
TITLE: Neuropeptide Y: a promising therapeutic target
AUTHOR(S): Dhanoa, Dale S.
CORPORATE SOURCE: Synaptic Pharmaceutical Corporation, Paramus, NJ, 07652 1410, USA
SOURCE: Expert Opinion on Therapeutic Patents (1995), 5(5), 391-6
CODEN: EOTPEG; ISSN: 1354-3776
PUBLISHER: Ashley Publications
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review, with 65 refs. Neuropeptide Y is one of the most abundant and widely distributed peptides in both the central and peripheral nervous systems. It plays important physiol. and pathophysiol. roles in cardiovascular, eating and sleep disorders as well as depression, anxiety, pain, cocaine withdrawal and sexual dysfunction. Thus, it offers promising opportunities for therapeutic intervention. The patent literature in the neuropeptide Y area of drug discovery is examined and the therapeutic value of the latest pharmacol. tools and agents are discussed.

L7 ANSWER 37 OF 39 MEDLINE on STN
ACCESSION NUMBER: 1995357007 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7630583
TITLE: Sexual function in altered physiological states: comparison of effects of hypertension, diabetes, hyperprolactinemia, and others to "normal" aging in male rats.
AUTHOR: Clark J T
CORPORATE SOURCE: Department of Physiology, Meharry Medical College, Nashville, TN 37208, USA.
CONTRACT NUMBER: GM-08037 (United States NIGMS)
HL-02482 (United States NHLBI)
RR-03032 (United States NCRR)
SOURCE: Neuroscience and biobehavioral reviews, (1995 Summer) Vol. 19, No. 2, pp. 279-302. Ref: 197
Journal code: 7806090. ISSN: 0149-7634.
PUB. COUNTRY: United States
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199509
ENTRY DATE: Entered STN: 21 Sep 1995
Last Updated on STN: 21 Sep 1995
Entered Medline: 7 Sep 1995
AB In this review, we examine the changes in sexual function that accompany deviations from "normal" physiological states. We propose that the changes one observes in many altered physiological states should not be viewed in isolation. We describe our paradigms for assessing sexual

function, and proceed to evaluate how sexual function changes with hormonal deprivation and aging, in rat models for hypertension, in severe hyperprolactinemia, in streptozotocin-induced diabetes, after chronic alcohol intake, after chronic morphine administration, and after exposure to the heavy metal, cadmium. We will provide evidence for the involvement of adrenergic transmitters and two neuropeptides, neuropeptide Y and somatostatin, in the neuroendocrine regulation of sexual behavior. Finally, we compare and contrast the changes observed relative to the changes seen in "normal" aging in rats. The sequence of age-related changes in sexual function is distinct. The first change observed is a decrement in ex copula erectile reflexes. Next are decreases in ejaculatory threshold, followed shortly by increases in initiation and reinitiation of copulation after ejaculation. This is followed by a decrement in the number of males copulating to ejaculation. Finally, there is a failure to initiate the copulatory process. This sequelae is relatively common, being evident after castration, with hyperprolactinemia, and after exposure to cadmium. The data available for sexual function in hypertension is incomplete and modified by the etiology, but a suggestion for this sequelae is seen in SHR. In contrast, sexual dysfunction associated with chronic morphine administration appears to be due to an initial deficit in motivational aspects. Testosterone reverses sexual dysfunction associated with castration, but not with idiopathic sexual inactivity, nor with sexual dysfunction associated with aging, diabetes, or chronic morphine administration. Comparing sexual function in rat models for hypertension, diabetes and chronic ethanol leads to the conclusion that increases in blood pressure, like decreases in testosterone, cannot be the primary causal factor for sexual dysfunction. Age, hormonal history of the subject, and the age at castration influence changes in sexual function. Age-related sexual dysfunction appears to be contributed to by changes in adrenergic-neuropeptidergic, to include sympathetic, systems. Site-specific administration of NPY induces alterations in parameters of copulatory behavior which mimic those seen in aging and the retention of ejaculatory behavior with aging is associated with site-selective attenuation (or reversal) of age-associated changes in NPY content. Yohimbine enhances copulatory activity in castrated and aging rats, and attenuates or reverses the antisexual effects of clonidine, epinephrine and somatostatin.(ABSTRACT TRUNCATED AT 400 WORDS)

L7 ANSWER 38 OF 39 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:340923 BIOSIS
DOCUMENT NUMBER: PREV200100340923
TITLE: Aminotriazole compounds.
AUTHOR(S): Fauchere, Jean-Luc [Inventor, Reprint author]; Ortuno, Jean-Claude [Inventor]; Duhault, Jacques [Inventor]; Boutin, Jean Albert [Inventor]; Levens, Nigel [Inventor]
CORPORATE SOURCE: Saint Cloud, France
ASSIGNEE: Adir et Compagnie, Courbevoie, France
PATENT INFORMATION: US 6245916 20010612
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (June 12, 2001) Vol. 1247, No. 2. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 18 Jul 2001
Last Updated on STN: 19 Feb 2002

AB Compound of formula (I): ##STR1## wherein: n is 0 or 1, W represents --CO-- or S(O)q and q is 0, 1 or 2, G represents a G1, G2, G3 or G4 group as defined in the description, Z represents alkyl, aryl, heteroaryl,

arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted. A represents a grouping selected from --A2 --, --A1 --A2 --, --A2 --A1 -- and --A1 --A2 --A1 -- wherein A1 is alkylene and A2 represents phenylene, cycloalkylene, naphthylene or heteroarylene each optionally substituted, R represents hydrogen, alkyl, aryl, heteroaryl, arylalkyl arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkenyl each optionally substituted, R1 represents alkyl, aryl, heteroary, arylalkyl arylalkenyl, arylalkynyl, heteroarylalkenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, and medicinal products containing the same which are useful as Neuropeptide Y receptor ligands.

L7 ANSWER 39 OF 39 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001009795 EMBASE
TITLE: Melanocortin receptors: New opportunities in drug discovery.
AUTHOR: Wikberg, J.E.S. (correspondence)
CORPORATE SOURCE: Dept. of Pharmaceutical Biosciences, Division of Pharmacology, Uppsala University, Box 591 BMC, SE-751 24 Uppsala, Sweden. Jarl.Wikberg@farmbio.uu.se
SOURCE: Expert Opinion on Therapeutic Patents, (2001) Vol. 11, No. 1, pp. 61-76.
Refs: 43
ISSN: 1354-3776 CODEN: EOTPEG
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 003 Endocrinology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
039 Pharmacy
008 Neurology and Neurosurgery
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 19 Jan 2001
Last Updated on STN: 19 Jan 2001

AB The cloning of five different subtypes of melanocortin receptors, MC(1-5), have provided new opportunities for the discovery of drugs that may be useful for the treatment of a variety of clinically important conditions, including MC(1) receptor agonists for inflammatory diseases, MC(3) receptor agonists for sexual dysfunctions and MC(4) receptor agonists and antagonists for treatment of obesity, anorexia and drug abuse. This review discusses patents covering the cloning of the MC receptors, the endogenous MC receptor antagonists agouti signalling peptide and agouti related protein and novel compounds target towards the MC receptors.

=> d 20-29 L7 ibib abs

L7 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:391522 CAPLUS
DOCUMENT NUMBER: 136:395983
TITLE: Bombesin receptor antagonists, and combinations with other agents, for the treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 225 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2002040008	A2	20020523	WO 2001-GB5018		20011114	<--
WO 2002040008	A3	20020822				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
WO 2002040022	A1	20020523	WO 2000-GB4380		20001117	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
CA 2429106	A1	20020523	CA 2001-2429106		20011114	<--
AU 2002023802	A	20020527	AU 2002-23802		20011114	<--
EP 1333824	A2	20030813	EP 2001-994552		20011114	<--
EP 1333824	B1	20050907				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
BR 2001015364	A	20030923	BR 2001-15364		20011114	<--
HU 2003001892	A2	20031128	HU 2003-1892		20011114	<--
HU 2003001892	A3	20050628				
JP 2004522710	T	20040729	JP 2002-542382		20011114	<--
NZ 525415	A	20041126	NZ 2001-525415		20011114	<--
AT 303804	T	20050915	AT 2001-994552		20011114	<--
MX 2003PA03482	A	20040910	MX 2003-PA3482		20030416	<--
US 20040087561	A1	20040506	US 2003-416934		20031204	<--
PRIORITY APPLN. INFO.:			WO 2000-GB4380	W	20001117	<--
			GB 2001-9910	A	20010423	<--
			GB 2001-11037	A	20010504	<--
			WO 2001-GB5018	W	20011114	<--

OTHER SOURCE(S): MARPAT 136:395983

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V inhibitors, neutral endopeptidase inhibitors, and lasofoxifene. Preparation of compds. of the invention is described.

L7 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:368993 CAPLUS
DOCUMENT NUMBER: 136:386129
TITLE: Preparation of 2,6-substituted-8-phenyl-7H-purines as neuropeptide Y antagonists
INVENTOR(S): Elliott, Richard L.

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20020058671	A1	20020516	US 2001-819368		20010328	<--
US 6511984	B2	20030128				
US 20020061897	A1	20020523	US 2001-819366		20010328	<--
US 20030100546	A1	20030529	US 2002-225663		20020821	<--
US 6649759	B2	20031118				
PRIORITY APPLN. INFO.:			US 2000-193087P	P	20000330	<--
			US 2000-193101P	P	20000330	<--
			US 2000-217165P	P	20000710	<--
			US 2001-819366	A1	20010328	<--

OTHER SOURCE(S): MARPAT 136:386129
GI



I

AB The title compds. [I; X = NR4R5 (wherein R4, R5 = alkyl, alkenyl, cycloalkyl, etc.; or NR4R5 = (un)substituted heterocyclyl); Y = alkyl, alkoxyalkyl, aryl, etc.; R3 = (un)substituted (hetero)aryl] which are neuropeptide antagonists, and are effective in treatment of feeding disorders, cardiovascular diseases and other physiol. disorders related to an excess of neuropeptide Y, were prepared Thus, oxidative condensation of 2,4-dihydroxy-5,6-diaminopyrimidine sulfate with benzoic acid followed by subsequent conversion of the dihydroxy compound to 2,6-dichloro-8-phenyl-7H-purine, and nucleophilic displacement of the chloride atom with pyrrolidine afforded I [X = pyrrolidino; Y = Cl; R3 = Ph] which showed Ki of < 1000 nM against NPY-5 receptor binding.

L7 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:51273 CAPLUS
DOCUMENT NUMBER: 136:96099
TITLE: Treatment of male sexual dysfunction
INVENTOR(S): Naylor, Alasdair Mark; Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002003995	A2	20020117	WO 2001-IB1187	20010702	<--
WO 2002003995	A3	20020418			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 20020052370	A1	20020502	US 2001-893585	20010628	<--
CA 2414112	A1	20020117	CA 2001-2414112	20010702	<--
AU 2001069353	A	20020121	AU 2001-69353	20010702	<--
EP 1296687	A2	20030402	EP 2001-947709	20010702	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

HU 2003001660	A2	20030929	HU 2003-1660	20010702	<--
JP 2004502735	T	20040129	JP 2002-508449	20010702	<--
NZ 522931	A	20050324	NZ 2001-522931	20010702	<--
ZA 2003000121	A	20040121	ZA 2003-121	20030106	<--
ZA 2003000120	A	20040126	ZA 2003-120	20030106	<--
ZA 2003004460	A	20040624	ZA 2003-4460	20030609	<--
US 20060041014	A1	20060223	US 2005-170397	20050628	<--

PRIORITY APPLN. INFO.:		GB 2000-16684	A	20000706	<--
		GB 2000-30647	A	20001215	<--
		GB 2001-6167	A	20010313	<--
		GB 2001-8483	A	20010404	<--
		US 2000-219100P	P	20000718	<--
		GB 2001-1584	A	20010122	<--
		US 2001-265358P	P	20010131	<--
		US 2001-274957P	P	20010312	<--
		US 2001-895367	A3	20010629	<--
		WO 2001-IB1187	W	20010702	<--

OTHER SOURCE(S): MARPAT 136:96099

AB The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.

L7 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:885763 CAPLUS
DOCUMENT NUMBER: 136:15253
TITLE: Melanocortin receptor agonists, and preparation thereof, for therapeutic use
INVENTOR(S): Bakshi, Raman Kumar; Nargund, Ravi P.; Ye, Zhixiong
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001091752	A1	20011206	WO 2001-US17014	20010525	<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2410597	A1	20011206	CA 2001-2410597		20010525 <--
EP 1289526	A1	20030312	EP 2001-939460		20010525 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003534377	T	20031118	JP 2001-587767		20010525 <--
AU 2001264977	B2	20050414	AU 2001-264977		20010525 <--
US 20020004512	A1	20020110	US 2001-867309		20010529 <--
US 6376509	B2	20020423			
PRIORITY APPLN. INFO.:			US 2000-207918P	P	20000530 <--
			WO 2001-US17014	W	20010525 <--

OTHER SOURCE(S): MARPAT 136:15253

GI



I

AB The invention discloses compds. and derivs. thereof which are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, e.g. obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Preparation of e.g. I is described.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2001:864708 CAPLUS
DOCUMENT NUMBER:	136:693
TITLE:	Method using a neurotensin receptor ligand for treating obesity and other disorders
INVENTOR(S):	Hadcock, John Richard Neville
PATENT ASSIGNEE(S):	Pfizer Products Inc., USA
SOURCE:	Eur. Pat. Appl., 30 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1157695	A1	20011128	EP 2001-303855	20010427 <--
EP 1157695	B1	20060628		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
US 20010046956	A1	20011129	US 2001-841276	20010424 <--
US 6699832	B2	20040302		
CA 2345180	A1	20011027	CA 2001-2345180	20010425 <--
ZA 2001003365	A	20021025	ZA 2001-3365	20010425 <--
HU 2001001666	A2	20020228	HU 2001-1666	20010426 <--
HU 2001001666	A3	20030328		
NZ 511354	A	20030328	NZ 2001-511354	20010426 <--
JP 2002275092	A	20020925	JP 2001-130680	20010427 <--
AT 331518	T	20060715	AT 2001-303855	20010427 <--
ES 2264679	T3	20070116	ES 2001-303855	20010427 <--

PRIORITY APPLN. INFO.: US 2000-199951P P 20000427 <--

AB Methods are provided for treating obesity, diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia using a neurotensin receptor ligand. The invention also provides pharmaceutical compns. and kits that comprise a neurotensin receptor ligand.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:763235 CAPLUS
DOCUMENT NUMBER: 135:314399
TITLE: Detection of variations in the DNA methylation profile of genes in the determining the risk of disease
INVENTOR(S): Berlin, Kurt; Piepenbrock, Christian; Olek, Alexander
PATENT ASSIGNEE(S): Epigenomics A.-G., Germany
SOURCE: PCT Int. Appl., 636 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 69
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077373	A2	20011018	WO 2001-DE1486	20010406 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10019058	A1	20011220	DE 2000-10019058	20000406 <--
WO 2001077373	A2	20011018	WO 2001-XA1486	20010406 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG				
WO 2001077373	A2	20011018	WO 2001-XB1486	20010406 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG

AU 2001073840	A	20011023	AU 2001-73840	20010406	<--
AU 2001077487	A	20011023	AU 2001-77487	20010406	<--
EP 1278892	A1	20030129	EP 2001-940158	20010406	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EP 1360319	A2	20031112	EP 2001-955278	20010406	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
AT 339520	T	20061015	AT 2002-90203	20020605	
ES 2272636	T3	20070501	ES 2002-90203	20020605	
US 20040067491	A1	20040408	US 2003-240454	20030311	<--
AU 2003204553	A1	20040108	AU 2003-204553	20030605	
AU 2003204553	B2	20071129			
JP 2004008217	A	20040115	JP 2003-160375	20030605	
US 20040023279	A1	20040205	US 2003-455212	20030605	
US 20070026393	A1	20070201	US 2003-240970	20030711	<--
AU 2006203475	A1	20060831	AU 2006-203475	20060811	<--
AU 2006213968	A1	20061019	AU 2006-213968	20060915	<--
AU 2006225250	A1	20061026	AU 2006-225250	20061005	<--
PRIORITY APPLN. INFO.:			DE 2000-10019058 A	20000406	<--
			DE 2000-10019173 A	20000407	<--
			DE 2000-10032529 A	20000630	<--
			DE 2000-10043826 A	20000901	<--
			AU 2001-275663 A	20010406	<--
			AU 2001-276331 A3	20010406	<--
			AU 2001-75663 A	20010406	<--
			WO 2001-DE1486 W	20010406	<--
			WO 2001-EP4016 W	20010406	<--
			EP 2002-90203 A	20020605	
			AU 2006-230475 A	20060811	

AB The invention relates to an oligonucleotide kit as probe for the detection of relevant variations in the DNA methylation of a target group of genes. The invention further relates to the use of the same for determining the gene variant with regard to DNA methylation, a medical device, using an oligonucleotide kit, a method for determining the methylation state of an individual and a method for the establishment of a model for establishing the probability of onset of a disease state in an individual. Such diseases may be: undesired pharmaceutical side-effects; cancerous diseases; CNS dysfunctions, injuries or diseases; aggressive symptoms or relational disturbances; clin., psychol. and social consequences of brain injury; psychotic disorders and personality disorders; dementia and/or associated syndromes; cardiovascular disease, dysfunction and damage; dysfunction, damage or disease of the gastrointestinal tract; dysfunction, damage or disease of the respiratory system; injury, inflammation, infection, immunity and/or anastasis; dysfunction, damage or disease of the body as an abnormal development process; dysfunction, damage or disease of the skin, muscle, connective tissue or bones; endocrine and metabolic dysfunction, damage or disease; headaches or sexual dysfunction. This abstract record is one of several records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

L7 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:636055 CAPLUS

DOCUMENT NUMBER: 135:211050
TITLE: Preparation of imidazoline compounds as antagonists of neuropeptide Y receptor
INVENTOR(S): Sato, Nagaaki; Okamoto, Osamu; Jitsuoka, Makoto; Nagai, Keita; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Fukami, Takehiro
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062738	A1	20010830	WO 2001-JP1312	20010222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2400659	A1	20010830	CA 2001-2400659	20010222 <--
AU 2001034128	A	20010903	AU 2001-34128	20010222 <--
EP 1264826	A1	20021211	EP 2001-906215	20010222 <--
EP 1264826	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2001234128	B2	20041111	AU 2001-234128	20010222 <--
AT 292119	T	20050415	AT 2001-906215	20010222 <--
ES 2236178	T3	20050716	ES 2001-906215	20010222 <--
US 20030158418	A1	20030821	US 2002-204267	20020925 <--
US 7064142	B2	20060620		
US 20060135559	A1	20060622	US 2006-348459	20060207 <--

PRIORITY APPLN. INFO.: JP 2000-45042 A 20000222 <--
WO 2001-JP1312 W 20010222 <--
US 2002-204267 A3 20020925

OTHER SOURCE(S): MARPAT 135:211050
GI



I







AB Compds. represented by the general formula (I) [wherein Ar1, Ar2, Ar3 = aryl or heteroaryl each optionally having substituents selected from cyano, halo, NO2, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower cycloalkyl-lower alkyl, lower alkenyl, lower alkylamino, di-lower alkylamino, lower alkanoylamino, lower alkylsulfonylamino, arylsulfonylamino, HO, lower alkoxy, halo-lower alkoxy, aryloxy, heteroaryloxy, lower alkylthio, CO2H, CHO, lower alkanoyl, lower alkoxycarbonyl, CONH2, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkylsulfonyl, arylsulfonyl, aryl, and heteroaryl; n = 0,1; R1 = lower cycloalkyl, Ar3, Q, Q1, Q2; R1, R2 = H, lower cycloalkyl, lower alkenyl, lower alkyl optionally having substituents selected from halo, lower alkylamino, di-lower alkylamino, lower alkanoylamino, HO, lower alkoxy, CHO, lower alkoxycarbonyl, lower alkylcarbamoyl, and di-lower alkylcarbamoyl; wherein R10 = R11 = H, or R10 and R11 together represents oxo; X, Y = CH2, CH2CH2, NR12 (wherein R12 = H, lower alkyl), O, S; Z = CH, N; with the proviso that when R2 and R3 are simultaneously hydrogen, Ar1, Ar2 and R1 do not simultaneously represent unsubstituted phenyl] or salts or esters thereof are prepared Theses compds. are useful as therapeutic agents for treating various neuropeptide Y (NPY)-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm, and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alc. dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma. Thus, 46.5 mg 2,4-dicyanopyridine and 24 mg ytterbium trifluoromethanesulfonate were added to a solution of 100 mg (2S)-1-(4-fluorophenyl)-1-(6-fluoro-3-pyridyl)-1,2-propanediamine in 0.25 mL PhMe and stirred at 100° for 5 h to give 106 mg optically active (5S)-2-(4-cyano-2-pyridyl)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridyl)-5-methyl-2-imidazolidine (II). II in vitro showed IC50 of 1.7 nM for inhibiting the binding of [125I]peptide YY to human NPY receptor. Tablet formulations containing 2-(3-cyanophenyl)-4,4-bis(4-fluorophenyl)-2-imidazolidine were prepared

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:338075 CAPLUS
DOCUMENT NUMBER: 134:336238
TITLE: NEP (neutral endopeptidase) inhibitors for the treatment of female sexual dysfunction
INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 124 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097719	A1	20010509	EP 2000-309722	20001103 <--
EP 1097719	B1	20041222		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO

EP 1481667 A1 20041201 EP 2004-20972 20001103 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY, TR

AT 285249 T 20050115 AT 2000-309722 20001103 <--

PT 1097719 T 20050429 PT 2000-309722 20001103 <--

ES 2233297 T3 20050616 ES 2000-309722 20001103 <--

ZA 2000006374 A 20020506 ZA 2000-6374 20001106 <--

ZA 2000006375 A 20020506 ZA 2000-6375 20001106 <--

ZA 2000006376 A 20020506 ZA 2000-6376 20001106 <--

ZA 2000006378 A 20020506 ZA 2000-6378 20001106 <--

AU 781186 B2 20050512 AU 2000-71411 20001106 <--

AU 781400 B2 20050519 AU 2000-71407 20001106 <--

AU 781403 B2 20050519 AU 2000-71408 20001106 <--

CA 2323183 A1 20010508 CA 2000-2323183 20001107 <--

CA 2323191 A1 20010508 CA 2000-2323191 20001107 <--

CA 2323464 A1 20010508 CA 2000-2323464 20001107 <--

CA 2324484 A1 20010508 CA 2000-2324484 20001107 <--

NO 2000005618 A 20010509 NO 2000-5618 20001107 <--

NO 2000005661 A 20010509 NO 2000-5661 20001107 <--

NO 2000005662 A 20010509 NO 2000-5662 20001107 <--

HU 2000004347 A2 20010628 HU 2000-4347 20001107 <--

HU 2000004348 A2 20010628 HU 2000-4348 20001107 <--

HU 2000004349 A2 20010628 HU 2000-4349 20001107 <--

HU 2000004350 A2 20010628 HU 2000-4350 20001107 <--

CN 1320426 A 20011107 CN 2000-137665 20001107 <--

CN 1322526 A 20011121 CN 2000-137671 20001107 <--

CN 1328824 A 20020102 CN 2000-137670 20001107 <--

NZ 508006 A 20020628 NZ 2000-508006 20001107 <--

NZ 508007 A 20020628 NZ 2000-508007 20001107 <--

NZ 508011 A 20020628 NZ 2000-508011 20001107 <--

NZ 508012 A 20020628 NZ 2000-508012 20001107 <--

BR 2000005266 A 20030408 BR 2000-5266 20001107 <--

CN 1575816 A 20050209 CN 2004-10071390 20001107 <--

CN 1636597 A 20050713 CN 2004-10085955 20001107 <--

JP 2001206855 A 20010731 JP 2000-339905 20001108 <--

JP 2001213802 A 20010807 JP 2000-339853 20001108 <--

JP 2001247478 A 20010911 JP 2000-339949 20001108 <--

JP 2001247479 A 20010911 JP 2000-339957 20001108 <--

BR 2000005276 A 20030408 BR 2000-5276 20001108 <--

BR 2000005299 A 20030415 BR 2000-5299 20001108 <--

US 6734186 B1 20040511 US 2000-708392 20001108 <--

US 20040254153 A1 20041216 US 2003-686390 20031015 <--

US 20050020547 A1 20050127 US 2003-686282 20031015 <--

US 20050070499 A1 20050331 US 2003-686349 20031015 <--

IN 2004DE00033 A 20070504 IN 2004-DE33 20040107 <--

KR 2004074021 A 20040821 KR 2004-50971 20040701 <--

KR 2004074022 A 20040821 KR 2004-50972 20040701 <--

KR 2004074023 A 20040821 KR 2004-50973 20040701 <--

JP 2005013237 A 20050120 JP 2004-268608 20040915 <--

JP 2005021167 A 20050127 JP 2004-267669 20040915 <--

JP 2005043377 A 20050217 JP 2004-269807 20040916 <--

JP 2005070055 A 20050317 JP 2004-269732 20040916 <--

AU 2005201482 A1 20050505 AU 2005-201482 20050407 <--

AU 2005202166 A1 20050616 AU 2005-202166 20050518 <--

AU 2005202750 A1 20050721 AU 2005-202750 20050623 <--

JP 2005350482 A 20051222 JP 2005-233224 20050811 <--

PRIORITY APPLN. INFO.: GB 1999-26437 A 19991108 <--

GB 2000-4021 A 20000218 <--

GB 2000-13001 A 20000526 <--

GB 2000-16563 A 20000705 <--

GB 2000-17141 A 20000712 <--

US 2000-175161P	P	20000107	<--
US 2000-192962P	P	20000329	<--
US 2000-217479P	P	20000711	<--
US 2000-221014P	P	20000727	<--
US 2000-221093P	P	20000727	<--
EP 2000-309722	A3	20001103	<--
AU 2000-71408	A3	20001106	<--
CN 2000-137670	A3	20001107	<--
KR 2000-65740	A3	20001107	<--
KR 2000-65863	A3	20001107	<--
KR 2000-65868	A3	20001107	<--
JP 2000-339853	A3	20001108	<--
JP 2000-339905	A3	20001108	<--
JP 2000-339949	A3	20001108	<--
JP 2000-339957	A3	20001108	<--
US 2000-708392	A3	20001108	<--

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal dysfunction, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an inhibitor of NEP (neutral endopeptidase; EC 3.4.24.11).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:338074 CAPLUS
DOCUMENT NUMBER: 134:336237
TITLE: Neuropeptide Y (NPY) antagonists for the treatment of female sexual dysfunction
INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 165 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1097718	A1	20010509	EP 2000-309720	20001103	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
AT 285249	T	20050115	AT 2000-309722	20001103	<--
PT 1097719	T	20050429	PT 2000-309722	20001103	<--
ES 2233297	T3	20050616	ES 2000-309722	20001103	<--
ZA 2000006374	A	20020506	ZA 2000-6374	20001106	<--
ZA 2000006375	A	20020506	ZA 2000-6375	20001106	<--
ZA 2000006376	A	20020506	ZA 2000-6376	20001106	<--
ZA 2000006378	A	20020506	ZA 2000-6378	20001106	<--
AU 781186	B2	20050512	AU 2000-71411	20001106	<--
AU 781400	B2	20050519	AU 2000-71407	20001106	<--
AU 781403	B2	20050519	AU 2000-71408	20001106	<--
CA 2323183	A1	20010508	CA 2000-2323183	20001107	<--
CA 2323191	A1	20010508	CA 2000-2323191	20001107	<--
CA 2323464	A1	20010508	CA 2000-2323464	20001107	<--
CA 2324484	A1	20010508	CA 2000-2324484	20001107	<--
NO 2000005618	A	20010509	NO 2000-5618	20001107	<--

NO	2000005661	A	20010509	NO	2000-5661	20001107 <--
NO	2000005662	A	20010509	NO	2000-5662	20001107 <--
HU	2000004347	A2	20010628	HU	2000-4347	20001107 <--
HU	2000004348	A2	20010628	HU	2000-4348	20001107 <--
HU	2000004349	A2	20010628	HU	2000-4349	20001107 <--
HU	2000004350	A2	20010628	HU	2000-4350	20001107 <--
CN	1320426	A	20011107	CN	2000-137665	20001107 <--
CN	1322526	A	20011121	CN	2000-137671	20001107 <--
CN	1328824	A	20020102	CN	2000-137670	20001107 <--
NZ	508006	A	20020628	NZ	2000-508006	20001107 <--
NZ	508007	A	20020628	NZ	2000-508007	20001107 <--
NZ	508011	A	20020628	NZ	2000-508011	20001107 <--
NZ	508012	A	20020628	NZ	2000-508012	20001107 <--
BR	2000005266	A	20030408	BR	2000-5266	20001107 <--
CN	1575816	A	20050209	CN	2004-10071390	20001107 <--
CN	1636597	A	20050713	CN	2004-10085955	20001107 <--
JP	2001206855	A	20010731	JP	2000-339905	20001108 <--
JP	2001213802	A	20010807	JP	2000-339853	20001108 <--
JP	2001247478	A	20010911	JP	2000-339949	20001108 <--
JP	2001247479	A	20010911	JP	2000-339957	20001108 <--
BR	2000005276	A	20030408	BR	2000-5276	20001108 <--
BR	2000005299	A	20030415	BR	2000-5299	20001108 <--
US	6734186	B1	20040511	US	2000-708392	20001108 <--
US	20040254153	A1	20041216	US	2003-686390	20031015 <--
US	20050020547	A1	20050127	US	2003-686282	20031015 <--
US	20050070499	A1	20050331	US	2003-686349	20031015 <--
IN	2004DE00033	A	20070504	IN	2004-DE33	20040107 <--
KR	2004074021	A	20040821	KR	2004-50971	20040701 <--
KR	2004074022	A	20040821	KR	2004-50972	20040701 <--
KR	2004074023	A	20040821	KR	2004-50973	20040701 <--
JP	2005013237	A	20050120	JP	2004-268608	20040915 <--
JP	2005021167	A	20050127	JP	2004-267669	20040915 <--
JP	2005043377	A	20050217	JP	2004-269807	20040916 <--
JP	2005070055	A	20050317	JP	2004-269732	20040916 <--
AU	2005201482	A1	20050505	AU	2005-201482	20050407 <--
AU	2005202166	A1	20050616	AU	2005-202166	20050518 <--
AU	2005202750	A1	20050721	AU	2005-202750	20050623 <--
JP	2005350482	A	20051222	JP	2005-233224	20050811 <--

PRIORITY APPLN. INFO.:

GB	1999-26437	A	19991108 <--
GB	2000-4021	A	20000218 <--
GB	2000-13001	A	20000526 <--
GB	2000-16563	A	20000705 <--
GB	2000-17141	A	20000712 <--
US	2000-175161P	P	20000107 <--
US	2000-192962P	P	20000329 <--
US	2000-217479P	P	20000711 <--
US	2000-221014P	P	20000727 <--
US	2000-221093P	P	20000727 <--
AU	2000-71408	A3	20001106 <--
CN	2000-137670	A3	20001107 <--
KR	2000-65740	A3	20001107 <--
KR	2000-65863	A3	20001107 <--
KR	2000-65868	A3	20001107 <--
JP	2000-339853	A3	20001108 <--
JP	2000-339905	A3	20001108 <--
JP	2000-339949	A3	20001108 <--
JP	2000-339957	A3	20001108 <--
US	2000-708392	A3	20001108 <--

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal dysfunction, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is

in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an antagonist of NPY. Preparation of neutral endopeptidase inhibitors, also use for treating the above disorders, is also described.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:338068 CAPLUS
DOCUMENT NUMBER: 134:348237
TITLE: Treatment of female sexual arousal dysfunction
INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 135 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097707	A1	20010509	EP 2000-309719	20001103 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 285249	T	20050115	AT 2000-309722	20001103 <--
PT 1097719	T	20050429	PT 2000-309722	20001103 <--
ES 2233297	T3	20050616	ES 2000-309722	20001103 <--
ZA 2000006374	A	20020506	ZA 2000-6374	20001106 <--
ZA 2000006375	A	20020506	ZA 2000-6375	20001106 <--
ZA 2000006376	A	20020506	ZA 2000-6376	20001106 <--
ZA 2000006378	A	20020506	ZA 2000-6378	20001106 <--
AU 781186	B2	20050512	AU 2000-71411	20001106 <--
AU 781400	B2	20050519	AU 2000-71407	20001106 <--
AU 781403	B2	20050519	AU 2000-71408	20001106 <--
CA 2323183	A1	20010508	CA 2000-2323183	20001107 <--
CA 2323191	A1	20010508	CA 2000-2323191	20001107 <--
CA 2323464	A1	20010508	CA 2000-2323464	20001107 <--
CA 2324484	A1	20010508	CA 2000-2324484	20001107 <--
NO 2000005618	A	20010509	NO 2000-5618	20001107 <--
NO 2000005661	A	20010509	NO 2000-5661	20001107 <--
NO 2000005662	A	20010509	NO 2000-5662	20001107 <--
HU 2000004347	A2	20010628	HU 2000-4347	20001107 <--
HU 2000004348	A2	20010628	HU 2000-4348	20001107 <--
HU 2000004349	A2	20010628	HU 2000-4349	20001107 <--
HU 2000004350	A2	20010628	HU 2000-4350	20001107 <--
CN 1320426	A	20011107	CN 2000-137665	20001107 <--
CN 1322526	A	20011121	CN 2000-137671	20001107 <--
CN 1328824	A	20020102	CN 2000-137670	20001107 <--
NZ 508006	A	20020628	NZ 2000-508006	20001107 <--
NZ 508007	A	20020628	NZ 2000-508007	20001107 <--
NZ 508011	A	20020628	NZ 2000-508011	20001107 <--
NZ 508012	A	20020628	NZ 2000-508012	20001107 <--
BR 2000005266	A	20030408	BR 2000-5266	20001107 <--
CN 1575816	A	20050209	CN 2004-10071390	20001107 <--
CN 1636597	A	20050713	CN 2004-10085955	20001107 <--
JP 2001206855	A	20010731	JP 2000-339905	20001108 <--
JP 2001213802	A	20010807	JP 2000-339853	20001108 <--
JP 2001247478	A	20010911	JP 2000-339949	20001108 <--
JP 2001247479	A	20010911	JP 2000-339957	20001108 <--
BR 2000005276	A	20030408	BR 2000-5276	20001108 <--

BR	2000005299	A	20030415	BR	2000-5299	20001108 <--
US	6734186	B1	20040511	US	2000-708392	20001108 <--
US	20040254153	A1	20041216	US	2003-686390	20031015 <--
US	20050020547	A1	20050127	US	2003-686282	20031015 <--
US	20050070499	A1	20050331	US	2003-686349	20031015 <--
IN	2004DE00033	A	20070504	IN	2004-DE33	20040107 <--
KR	2004074021	A	20040821	KR	2004-50971	20040701 <--
KR	2004074022	A	20040821	KR	2004-50972	20040701 <--
KR	2004074023	A	20040821	KR	2004-50973	20040701 <--
JP	2005013237	A	20050120	JP	2004-268608	20040915 <--
JP	2005021167	A	20050127	JP	2004-267669	20040915 <--
JP	2005043377	A	2005021?	JP	2004-269807	20040916 <--
JP	2005070055	A	2005031?	JP	2004-269732	20040916 <--
AU	2005201482	A1	20050505	AU	2005-201482	20050407 <--
AU	2005202166	A1	20050616	AU	2005-202166	20050518 <--
AU	2005202750	A1	20050721	AU	2005-202750	20050623 <--
JP	2005350482	A	20051222	JP	2005-233224	20050811 <--
PRIORITY APPLN. INFO.:				GB	1999-26437	A 19991108 <--
				GB	2000-4021	A 20000218 <--
				GB	2000-13001	A 20000526 <--
				GB	2000-16563	A 20000705 <--
				GB	2000-17141	A 20000712 <--
				US	2000-175161P	P 20000107 <--
				US	2000-192962P	P 20000329 <--
				US	2000-217479P	P 20000711 <--
				US	2000-221014P	P 20000727 <--
				US	2000-221093P	P 20000727 <--
				AU	2000-71408	A3 20001106 <--
				CN	2000-137670	A3 20001107 <--
				KR	2000-65740	A3 20001107 <--
				KR	2000-65863	A3 20001107 <--
				KR	2000-65868	A3 20001107 <--
				JP	2000-339853	A3 20001108 <--
				JP	2000-339905	A3 20001108 <--
				JP	2000-339949	A3 20001108 <--
				JP	2000-339957	A3 20001108 <--
				US	2000-708392	A3 20001108 <--

AB A method of treating a female suffering from female sexual dysfunction (FSD), in particular female sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d L7 15-28 ibib abs

L7 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:594869 CAPLUS

DOCUMENT NUMBER: 137:164897

TITLE: B-superfamily conotoxins and cDNAs and their use in pharmaceuticals and in drug screening

INVENTOR(S): Jones, Robert M.; Olivera, Baldomero M.; Watkins, Maren; Garrett, James E.

PATENT ASSIGNEE(S): Cognetix, Inc., USA; University of Utah Research Foundation

SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060923	A2	20020808	WO 2002-US2523	20020129 <--
WO 2002060923	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002245340	A1	20020812	AU 2002-245340	20020129 <--
US 20030170222	A1	20030911	US 2002-58053	20020129 <--
US 20040176278	A1	20040909	US 2004-838226	20040505 <--
US 20050271589	A1	20051208	US 2005-198847	20050808 <--
US 7115708	B2	20061003		
PRIORITY APPLN. INFO.:			US 2001-264323P	P 20010129 <--
			US 2002-58053	B1 20020129
			WO 2002-US2523	W 20020129
			US 2004-838226	B1 20040505

AB The present invention is directed to B-superfamily conotoxin peptides, derivs. or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivs. thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand-gated channels, and other receptors. The invention is further directed to the nucleic acid sequences encoding the B-superfamily conotoxin peptides and encoding B-superfamily conotoxin propeptides, as well as the B-superfamily conotoxin propeptides. Thus, the DNA encoding 75 novel preprotoxins of various Conus species and the encoded conotoxins are disclosed. Truncated forms of these conotoxins inhibited growth of human breast and pancreatic adenocarcinoma cells in culture. The binding of these truncated conotoxins to somatostation and melanocortin receptors was analyzed.

L7 ANSWER 16 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:575075 CAPLUS
DOCUMENT NUMBER: 137:140779
TITLE: Preparation of piperazine- and piperidine-derivatives as melanocortin receptor agonists
INVENTOR(S): Briner, Karin; Doecke, Christopher William; Mancoso, Vincent; Martinelli, Michael John; Richardson, Timothy Ivo; Rothhaar, Roger Ryan; Shi, Qing; Xie, Chaoyu
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 272 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059117	A1	20020801	WO 2002-US515	20020123 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2432985	A1	20020801	CA 2002-2432985	20020123	<--
AU 2002235322	A1	20020806	AU 2002-235322	20020123	<--
EP 1370558	A1	20031217	EP 2002-701922	20020123	<--
EP 1370558	B1	20050824			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004523530	T	20040805	JP 2002-559419	20020123	<--
AT 302773	T	20050915	AT 2002-701922	20020123	<--
ES 2246390	T3	20060216	ES 2002-714719	20020123	<--
ES 2247298	T3	20060301	ES 2002-701922	20020123	<--
US 20040082590	A1	20040429	US 2003-466248	20030711	<--
US 7186715	B2	20070306			
IN 2003KN00948	A	20050311	IN 2003-KN948	20030723	<--
PRIORITY APPLN. INFO.:			US 2001-263471P	P 20010123	<--
			WO 2001-US515	W 20020123	
			WO 2002-US515	W 20020123	

OTHER SOURCE(S): MARPAT 137:140779

GI



I

AB The compds. of formula I [G = CR1, or N; A = alkyl, or cycloalkyl; L and L1 = H, or (together) oxo ; T = substituted indolyl, or pyrazinyl; X = CH2, or CH2CH2; Z = (CH2)n; R1 = H, alkyl, Ph, alkylaryl, alkylcarboxamide, cycloalkyl, or oxo; R2 = H, halo, alkyl, alkylsulfonyl, cycloalkyl, alkylaryl, or haloalkyl; R3 = (un)substituted aryl, or thienyl; R4 = H, alkyl, cycloalkyl, etc.; R5 = NH2, NPh2, alkylamide, alkylsulfonylamide, NHCOH, NHCONH2, NHSO2NH2, (un)substituted heterocyclyl, etc.; n = 0-8, m = 0-1, and p = 0-4], pharmaceutically acceptable salts, or stereoisomers were prepared as melanocortin receptor agonists for treatment of obesity, diabetes and male and/or female sexual dysfunction. Thus, coupling of 2-[(2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-3-ylmethyl)amino]-3-(4-chlorophenyl)propionate with 3-(2-piperazin-1-yltrifluoromethylphenoxy)-S-pyrrolidine-1-carboxylic acid tert-Bu ester, followed by deprotection and addition of HCl, gave 3-D-(4-chlorophenyl)-1-[4-[5-trifluoromethyl-2-S-(pyrrolidin-3-yloxy)phenyl]piperazin-1-yl]-2-D-[(1,2,3,4-tetrahydroisoquinoline-3-ylmethyl)amino]propan-1-one hydrochloride in 84% yield.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:540258 CAPLUS
DOCUMENT NUMBER: 137:109267
TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020094977	A1	20020718	US 2001-7407	20011204 <--
US 6627636	B2	20030930		
US 20020013334	A1	20020131	US 2001-875155	20010606 <--
PRIORITY APPLN. INFO.:			US 2000-211595P P	20000615 <--
			US 2001-875155 A2	20010606 <--

OTHER SOURCE(S): MARPAT 137:109267
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis (no data). A multistep synthesis of II is reported.

L7 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:539674 CAPLUS
DOCUMENT NUMBER: 137:109273
TITLE: Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
INVENTOR(S): Urbanski, Maud J.; Gunnet, Joseph W., Jr.; Demarest, Keith T.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055514	A2	20020718	WO 2001-US51108	20011023 <--
WO 2002055514	A3	20021121		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2002243419	A1	20020724	AU	2002-243419		20011023 <--
US	20030073842	A1	20030417	US	2001-47841		20011023 <--
US	6653478	B2	20031125				
EP	1330451	A2	20030730	EP	2001-989314		20011023 <--
EP	1330451	B1	20080123				

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP	2004517872	T	20040617	JP	2002-556183		20011023 <--
AT	384711	T	20080215	AT	2001-989314		20011023 <--
ES	2300376	T3	20080616	ES	2001-989314		20011023 <--
PRIORITY APPLN. INFO.:				US	2000-243817P	P	20001027 <--
				WO	2001-US51108	W	20011023 <--

OTHER SOURCE(S): MARPAT 137:109273
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = aryl or heteroaryl having 0-4 heteroatoms selected from N, O and S; X = S, O, NH, and NCN; Y = S or O; R1 = 1-3 groups selected from H, halo, NO2, (un)substituted alkyl, alkoxy, etc.; R2 = H, (un)substituted alkyl; R3 = H, benzhydryl, (un)substituted alkyl, aryl, heteroaryl, etc.; R4 and R5 independently = H, (un)substituted alkyl, etc., or nonexistent when n = 0; n = 0-1; m = 0-1, with proviso that when m = 0, X = O, and R3 = (un)substituted heteroaryl, CO2Ra, and CONRaRb wherein Ra and Rb independently = (un)substituted alkyl, aryl, heteroaryl, heterocyclyl, or NRaRb ma be taken together to form a group selected from (un)substituted heteroaryl or heterocyclyl, then n = 0] and their pharmaceutically acceptable salts are prepared and disclosed as vasopressin receptor antagonists or neuropeptide Y modulators. Thus, II was prepared in 87% yield by addition of benzhydryl isothiocyanate to 4-(2-keto-1-benzimidazolinyl)piperidine. I were evaluated for their affinity with NPY-2 receptor, vasopressin-1a (V1a), -1b (V1b) and -2 (V2) receptors. For example, II ws responsible for 52% inhibition of NPY-2 at 10μM, 38% inhibition of V2 at 1μM, 0% inhibition of V1b at concns. up to 10μM, and possessed an IC50 value of 0.59 μM for V1a. As vasopressin antagonists and neuropeptide Y modulators, I are useful for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroks, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

L7 ANSWER 19 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2002:465801 CAPLUS
DOCUMENT NUMBER:	137:52344
TITLE:	Treatment of male sexual dysfunction
INVENTOR(S):	Naylor, Alasdair Mark; Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047670	A1	20020620	WO 2001-IB2399	20011210 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020028799	A1	20020307	US 2001-895367	20010629 <--
US 20020102707	A1	20020801	US 2001-905846	20010713 <--
US 6878529	B2	20050412		
CA 2431747	A1	20020620	CA 2001-2431747	20011210 <--
AU 2002020977	A	20020624	AU 2002-20977	20011210 <--
EP 1347750	A1	20031001	EP 2001-270206	20011210 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1496254	A	20040512	CN 2001-820556	20011210 <--
HU 2004000528	A2	20040628	HU 2004-528	20011210 <--
JP 2004522720	T	20040729	JP 2002-549244	20011210 <--
NZ 526925	A	20050324	NZ 2001-526925	20011210 <--
ZA 2003004460	A	20040624	ZA 2003-4460	20030609 <--
US 20060041014	A1	20060223	US 2005-170397	20050628 <--

PRIORITY APPLN. INFO.:

GB 2000-30647	A	20001215 <--
GB 2001-8730	A	20010406 <--
GB 2001-9910	A	20010423 <--
GB 2001-11037	A	20010504 <--
US 2001-895367	A	20010629 <--
US 2001-905846	A	20010713 <--
GB 2001-20679	A	20010824 <--
GB 2000-16684	A	20000706 <--
GB 2000-17387	A	20000714 <--
US 2000-219100P	P	20000718 <--
US 2000-220908P	P	20000726 <--
US 2001-265358P	P	20010131 <--
GB 2001-6167	A	20010313 <--
GB 2001-8483	A	20010404 <--
WO 2001-IB2399	W	20011210 <--

AB The use of an inhibitor of a neuropeptide Y (NPY), preferably of a NPY Y1 receptor, which inhibitor is selective for an NPY or NPY Y1 receptor associated with male genitalia, in the preparation/manufacture of a medicament for the treatment or prevention of male erectile dysfunction (MED).

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:391522 CAPLUS
DOCUMENT NUMBER: 136:395983
TITLE: Bombesin receptor antagonists, and combinations with

other agents, for the treatment of sexual dysfunction

INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002040008	A2	20020523	WO 2001-GB5018	20011114	<--
WO 2002040008	A3	20020822			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
WO 2002040022	A1	20020523	WO 2000-GB4380	20001117	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2429106	A1	20020523	CA 2001-2429106	20011114	<--
AU 2002023802	A	20020527	AU 2002-23802	20011114	<--
EP 1333824	A2	20030813	EP 2001-994552	20011114	<--
EP 1333824	B1	20050907			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001015364	A	20030923	BR 2001-15364	20011114	<--
HU 2003001892	A2	20031128	HU 2003-1892	20011114	<--
HU 2003001892	A3	20050628			
JP 2004522710	T	20040729	JP 2002-542382	20011114	<--
NZ 525415	A	20041126	NZ 2001-525415	20011114	<--
AT 303804	T	20050915	AT 2001-994552	20011114	<--
MX 2003PA03482	A	20040910	MX 2003-PA3482	20030416	<--
US 20040087561	A1	20040506	US 2003-416934	20031204	<--

PRIORITY APPLN. INFO.:			
	WO 2000-GB4380	W	20001117 <--
	GB 2001-9910	A	20010423 <--
	GB 2001-11037	A	20010504 <--
	WO 2001-GB5018	W	20011114 <--

OTHER SOURCE(S): MARPAT 136:395983

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V inhibitors, neutral endopeptidase inhibitors, and lasofoxifene. Preparation of

compds. of the invention is described.

L7 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:368993 CAPLUS
DOCUMENT NUMBER: 136:386129
TITLE: Preparation of 2,6-substituted-8-phenyl-7H-purines as neuropeptide Y antagonists
INVENTOR(S): Elliott, Richard L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020058671	A1	20020516	US 2001-819368	20010328 <--
US 6511984	B2	20030128		
US 20020061897	A1	20020523	US 2001-819366	20010328 <--
US 20030100546	A1	20030529	US 2002-225663	20020821 <--
US 6649759	B2	20031118		

PRIORITY APPLN. INFO.:
US 2000-193087P P 20000330 <--
US 2000-193101P P 20000330 <--
US 2000-217165P P 20000710 <--
US 2001-819366 A1 20010328 <--

OTHER SOURCE(S): MARPAT 136:386129
GI



I

AB The title compds. [I; X = NR4R5 (wherein R4, R5 = alkyl, alkenyl, cycloalkyl, etc.; or NR4R5 = (un)substituted heterocyclyl); Y = alkyl, alkoxyalkyl, aryl, etc.; R3 = (un)substituted (hetero)aryl] which are neuropeptide antagonists, and are effective in treatment of feeding disorders, cardiovascular diseases and other physiol. disorders related to an excess of neuropeptide Y, were prepared Thus, oxidative condensation of 2,4-dihydroxy-5,6-diaminopyrimidine sulfate with benzoic acid followed by subsequent conversion of the dihydroxy compound to 2,6-dichloro-8-phenyl-7H-purine, and nucleophilic displacement of the chloride atom with pyrrolidine afforded I [X = pyrrolidino; Y = Cl; R3 = Ph] which showed Ki of < 1000 nM against NPY-5 receptor binding.

L7 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:51273 CAPLUS
DOCUMENT NUMBER: 136:96099
TITLE: Treatment of male sexual dysfunction
INVENTOR(S): Naylor, Alasdair Mark; Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002003995	A2	20020117	WO 2001-IB1187	20010702	<--
WO 2002003995	A3	20020418			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 20020052370	A1	20020502	US 2001-893585	20010628	<--
CA 2414112	A1	20020117	CA 2001-2414112	20010702	<--
AU 2001069353	A	20020121	AU 2001-69353	20010702	<--
EP 1296687	A2	20030402	EP 2001-947709	20010702	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 2003001660	A2	20030929	HU 2003-1660	20010702	<--
JP 2004502735	T	20040129	JP 2002-508449	20010702	<--
NZ 522931	A	20050324	NZ 2001-522931	20010702	<--
ZA 2003000121	A	20040121	ZA 2003-121	20030106	<--
ZA 2003000120	A	20040126	ZA 2003-120	20030106	<--
ZA 2003004460	A	20040624	ZA 2003-4460	20030609	<--
US 20060041014	A1	20060223	US 2005-170397	20050628	<--

PRIORITY APPLN. INFO.:

GB 2000-16684	A	20000706	<--
GB 2000-30647	A	20001215	<--
GB 2001-6167	A	20010313	<--
GB 2001-8483	A	20010404	<--
US 2000-219100P	P	20000718	<--
GB 2001-1584	A	20010122	<--
US 2001-265358P	P	20010131	<--
US 2001-274957P	P	20010312	<--
US 2001-895367	A3	20010629	<--
WO 2001-IB1187	W	20010702	<--

OTHER SOURCE(S): MARPAT 136:96099

AB The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.

L7 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:885763 CAPLUS
DOCUMENT NUMBER: 136:15253
TITLE: Melanocortin receptor agonists, and preparation thereof, for therapeutic use
INVENTOR(S): Bakshi, Raman Kumar; Nargund, Ravi P.; Ye, Zhixiong
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091752	A1	20011206	WO 2001-US17014	20010525 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2410597	A1	20011206	CA 2001-2410597	20010525 <--
EP 1289526	A1	20030312	EP 2001-939460	20010525 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003534377	T	20031118	JP 2001-587767	20010525 <--
AU 2001264977	B2	20050414	AU 2001-264977	20010525 <--
US 20020004512	A1	20020110	US 2001-867309	20010529 <--
US 6376509	B2	20020423		
PRIORITY APPLN. INFO.:			US 2000-207918P P	20000530 <--
			WO 2001-US17014 W	20010525 <--

OTHER SOURCE(S): MARPAT 136:15253

GI



I

AB The invention discloses compds. and derivs. thereof which are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, e.g. obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Preparation of e.g. I is described.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:864708 CAPLUS

DOCUMENT NUMBER: 136:693

TITLE: Method using a neurotensin receptor ligand for

treating obesity and other disorders
INVENTOR(S): Hadcock, John Richard Neville
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1157695	A1	20011128	EP 2001-303855	20010427 <--
EP 1157695	B1	20060628		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
US 20010046956	A1	20011129	US 2001-841276	20010424 <--
US 6699832	B2	20040302		
CA 2345180	A1	20011027	CA 2001-2345180	20010425 <--
ZA 2001003365	A	20021025	ZA 2001-3365	20010425 <--
HU 2001001666	A2	20020228	HU 2001-1666	20010426 <--
HU 2001001666	A3	20030328		
NZ 511354	A	20030328	NZ 2001-511354	20010426 <--
JP 2002275092	A	20020925	JP 2001-130680	20010427 <--
AT 331518	T	20060715	AT 2001-303855	20010427 <--
ES 2264679	T3	20070116	ES 2001-303855	20010427 <--

PRIORITY APPLN. INFO.: US 2000-199951P P 20000427 <--

AB Methods are provided for treating obesity, diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia using a neurotensin receptor ligand. The invention also provides pharmaceutical compns. and kits that comprise a neurotensin receptor ligand.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:763235 CAPLUS
DOCUMENT NUMBER: 135:314399
TITLE: Detection of variations in the DNA methylation profile of genes in the determining the risk of disease
INVENTOR(S): Berlin, Kurt; Piepenbrock, Christian; Olek, Alexander
PATENT ASSIGNEE(S): Epigenomics A.-G., Germany
SOURCE: PCT Int. Appl., 636 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 69
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077373	A2	20011018	WO 2001-DE1486	20010406 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10019058	A1	20011220	DE 2000-10019058	20000406 <--

WO 2001077373 A2 20011018 WO 2001-XA1486 20010406 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG
WO 2001077373 A2 20011018 WO 2001-XB1486 20010406 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG
AU 2001073840 A 20011023 AU 2001-73840 20010406 <--
AU 2001077487 A 20011023 AU 2001-77487 20010406 <--
EP 1278892 A1 20030129 EP 2001-940158 20010406 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EP 1360319 A2 20031112 EP 2001-955278 20010406 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
AT 339520 T 20061015 AT 2002-90203 20020605
ES 2272636 T3 20070501 ES 2002-90203 20020605
US 20040067491 A1 20040408 US 2003-240454 20030311 <--
AU 2003204553 A1 20040108 AU 2003-204553 20030605
AU 2003204553 B2 20071129
JP 2004008217 A 20040115 JP 2003-160375 20030605
US 20040023279 A1 20040205 US 2003-455212 20030605
US 20070026393 A1 20070201 US 2003-240970 20030711 <--
AU 2006203475 A1 20060831 AU 2006-203475 20060811 <--
AU 2006213968 A1 20061019 AU 2006-213968 20060915 <--
AU 2006225250 A1 20061026 AU 2006-225250 20061005 <--
PRIORITY APPLN. INFO.: DE 2000-10019058 A 20000406 <--
DE 2000-10019173 A 20000407 <--
DE 2000-10032529 A 20000630 <--
DE 2000-10043826 A 20000901 <--
AU 2001-275663 A 20010406 <--
AU 2001-276331 A3 20010406 <--
AU 2001-75663 A 20010406 <--
WO 2001-DE1486 W 20010406 <--
WO 2001-EP4016 W 20010406 <--
EP 2002-90203 A 20020605
AU 2006-230475 A 20060811

AB The invention relates to an oligonucleotide kit as probe for the detection of relevant variations in the DNA methylation of a target group of genes. The invention further relates to the use of the same for determining the gene variant with regard to DNA methylation, a medical device, using an oligonucleotide kit, a method for determining the methylation state of an individual and a method for the establishment of a model for establishing the probability of onset of a disease state in an individual. Such diseases may be: undesired pharmaceutical side-effects; cancerous diseases; CNS dysfunctions, injuries or diseases; aggressive symptoms or relational disturbances; clin., psychol. and social consequences of brain injury; psychotic disorders and personality disorders; dementia and/or associated syndromes; cardiovascular disease, dysfunction and damage; dysfunction, damage or disease of the gastrointestinal tract; dysfunction, damage or disease of the respiratory system; injury, inflammation,

infection, immunity and/or anastasis; dysfunction, damage or disease of the body as an abnormal development process; dysfunction, damage or disease of the skin, muscle, connective tissue or bones; endocrine and metabolic dysfunction, damage or disease; headaches or sexual dysfunction. This abstract record is one of several records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

L7 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:636055 CAPLUS
DOCUMENT NUMBER: 135:211050
TITLE: Preparation of imidazoline compounds as antagonists of neuropeptide Y receptor
INVENTOR(S): Sato, Nagaaki; Okamoto, Osamu; Jitsuoka, Makoto; Nagai, Keita; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Fukami, Takehiro
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062738	A1	20010830	WO 2001-JP1312	20010222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2400659	A1	20010830	CA 2001-2400659	20010222 <--
AU 2001034128	A	20010903	AU 2001-34128	20010222 <--
EP 1264826	A1	20021211	EP 2001-906215	20010222 <--
EP 1264826	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2001234128	B2	20041111	AU 2001-234128	20010222 <--
AT 292119	T	20050415	AT 2001-906215	20010222 <--
ES 2236178	T3	20050716	ES 2001-906215	20010222 <--
US 20030158418	A1	20030821	US 2002-204267	20020925 <--
US 7064142	B2	20060620		
US 20060135559	A1	20060622	US 2006-348459	20060207 <--

PRIORITY APPLN. INFO.:			
	JP 2000-45042	A	20000222 <--
	WO 2001-JP1312	W	20010222 <--
	US 2002-204267	A3	20020925

OTHER SOURCE(S): MARPAT 135:211050
GI









AB Compds. represented by the general formula (I) [wherein Ar1, Ar2, Ar3 = aryl or heteroaryl each optionally having substituents selected from cyano, halo, NO2, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower cycloalkyl-lower alkyl, lower alkenyl, lower alkylamino, di-lower alkylamino, lower alkanoylamino, lower alkylsulfonylamino, arylsulfonylamino, HO, lower alkoxy, halo-lower alkoxy, aryloxy, heteroaryloxy, lower alkylthio, CO2H, CHO, lower alkanoyl, lower alkoxycarbonyl, CONH2, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkylsulfonyl, arylsulfonyl, aryl, and heteroaryl; n = 0,1; R1 = lower cycloalkyl, Ar3, Q, Q1, Q2; R1, R2 = H, lower cycloalkyl, lower alkenyl, lower alkyl optionally having substituents selected from halo, lower alkylamino, di-lower alkylamino, lower alkanoylamino, HO, lower alkoxy, CHO, lower alkoxycarbonyl, lower alkylcarbamoyl, and di-lower alkylcarbamoyl; wherein R10 = R11 = H, or R10 and R11 together represents oxo; X, Y = CH2, CH2CH2, NR12 (wherein R12 = H, lower alkyl), O, S; Z = CH, N; with the proviso that when R2 and R3 are simultaneously hydrogen, Ar1, Ar2 and R1 do not simultaneously represent unsubstituted phenyl] or salts or esters thereof are prepared Theses compds. are useful as therapeutic agents for treating various neuropeptide Y (NPY)-related diseases, for example, circulatory diseases including hypertension, kidney diseases, cardiac diseases, vasospasm, and arteriosclerosis; central nervous system diseases including hyperphagia, depression, anxiety, convulsion, epilepsy, dementia, pain, alc. dependence, and withdrawal symptoms due to abstinence from drugs; metabolic diseases including obesity, diabetes, hormonal disorders, hypercholesterolemia, and hyperlipidemia; sexual dysfunction and reproductive function disorders; digestive diseases including enterokinetic disorders; respiratory diseases; inflammation; or glaucoma. Thus, 46.5 mg 2,4-dicyanopyridine and 24 mg ytterbium trifluoromethanesulfonate were added to a solution of 100 mg (2S)-1-(4-fluorophenyl)-1-(6-fluoro-3-pyridyl)-1,2-propanediamine in 0.25 mL PhMe and stirred at 100° for 5 h to give 106 mg optically active (5S)-2-(4-cyano-2-pyridyl)-4-(4-fluorophenyl)-4-(6-fluoro-3-pyridyl)-5-methyl-2-imidazolidine (II). II in vitro showed IC50 of 1.7 nM for inhibiting the binding of [125I]peptide YY to human NPY receptor. Tablet formulations containing 2-(3-cyanophenyl)-4,4-bis(4-fluorophenyl)-2-imidazolidine were prepared

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:338075 CAPLUS
DOCUMENT NUMBER: 134:336238
TITLE: NEP (neutral endopeptidase) inhibitors for the

treatment of female sexual dysfunction

INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 124 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1097719	A1	20010509	EP 2000-309722	20001103	<--
EP 1097719	B1	20041222			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
EP 1481667	A1	20041201	EP 2004-20972	20001103	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY, TR					
AT 285249	T	20050115	AT 2000-309722	20001103	<--
PT 1097719	T	20050429	PT 2000-309722	20001103	<--
ES 2233297	T3	20050616	ES 2000-309722	20001103	<--
ZA 2000006374	A	20020506	ZA 2000-6374	20001106	<--
ZA 2000006375	A	20020506	ZA 2000-6375	20001106	<--
ZA 2000006376	A	20020506	ZA 2000-6376	20001106	<--
ZA 2000006378	A	20020506	ZA 2000-6378	20001106	<--
AU 781186	B2	20050512	AU 2000-71411	20001106	<--
AU 781400	B2	20050519	AU 2000-71407	20001106	<--
AU 781403	B2	20050519	AU 2000-71408	20001106	<--
CA 2323183	A1	20010508	CA 2000-2323183	20001107	<--
CA 2323191	A1	20010508	CA 2000-2323191	20001107	<--
CA 2323464	A1	20010508	CA 2000-2323464	20001107	<--
CA 2324484	A1	20010508	CA 2000-2324484	20001107	<--
NO 2000005618	A	20010509	NO 2000-5618	20001107	<--
NO 2000005661	A	20010509	NO 2000-5661	20001107	<--
NO 2000005662	A	20010509	NO 2000-5662	20001107	<--
HU 2000004347	A2	20010628	HU 2000-4347	20001107	<--
HU 2000004348	A2	20010628	HU 2000-4348	20001107	<--
HU 2000004349	A2	20010628	HU 2000-4349	20001107	<--
HU 2000004350	A2	20010628	HU 2000-4350	20001107	<--
CN 1320426	A	20011107	CN 2000-137665	20001107	<--
CN 1322526	A	20011121	CN 2000-137671	20001107	<--
CN 1328824	A	20020102	CN 2000-137670	20001107	<--
NZ 508006	A	20020628	NZ 2000-508006	20001107	<--
NZ 508007	A	20020628	NZ 2000-508007	20001107	<--
NZ 508011	A	20020628	NZ 2000-508011	20001107	<--
NZ 508012	A	20020628	NZ 2000-508012	20001107	<--
BR 2000005266	A	20030408	BR 2000-5266	20001107	<--
CN 1575816	A	20050209	CN 2004-10071390	20001107	<--
CN 1636597	A	20050713	CN 2004-10085955	20001107	<--
JP 2001206855	A	20010731	JP 2000-339905	20001108	<--
JP 2001213802	A	20010807	JP 2000-339853	20001108	<--
JP 2001247478	A	20010911	JP 2000-339949	20001108	<--
JP 2001247479	A	20010911	JP 2000-339957	20001108	<--
BR 2000005276	A	20030408	BR 2000-5276	20001108	<--
BR 2000005299	A	20030415	BR 2000-5299	20001108	<--
US 6734186	B1	20040511	US 2000-708392	20001108	<--
US 20040254153	A1	20041216	US 2003-686390	20031015	<--
US 20050020547	A1	20050127	US 2003-686282	20031015	<--
US 20050070499	A1	20050331	US 2003-686349	20031015	<--
IN 2004DE00033	A	20070504	IN 2004-DE33	20040107	<--

KR 2004074021	A	20040821	KR 2004-50971	20040701	<--
KR 2004074022	A	20040821	KR 2004-50972	20040701	<--
KR 2004074023	A	20040821	KR 2004-50973	20040701	<--
JP 2005013237	A	20050120	JP 2004-268608	20040915	<--
JP 2005021167	A	20050127	JP 2004-267669	20040915	<--
JP 2005043377	A	20050217	JP 2004-269807	20040916	<--
JP 2005070055	A	20050317	JP 2004-269732	20040916	<--
AU 2005201482	A1	20050505	AU 2005-201482	20050407	<--
AU 2005202166	A1	20050616	AU 2005-202166	20050518	<--
AU 2005202750	A1	20050721	AU 2005-202750	20050623	<--
JP 2005350482	A	20051222	JP 2005-233224	20050811	<--
PRIORITY APPLN. INFO.:			GB 1999-26437	A 19991108	<--
			GB 2000-4021	A 20000218	<--
			GB 2000-13001	A 20000526	<--
			GB 2000-16563	A 20000705	<--
			GB 2000-17141	A 20000712	<--
			US 2000-175161P	P 20000107	<--
			US 2000-192962P	P 20000329	<--
			US 2000-217479P	P 20000711	<--
			US 2000-221014P	P 20000727	<--
			US 2000-221093P	P 20000727	<--
			EP 2000-309722	A3 20001103	<--
			AU 2000-71408	A3 20001106	<--
			CN 2000-137670	A3 20001107	<--
			KR 2000-65740	A3 20001107	<--
			KR 2000-65863	A3 20001107	<--
			KR 2000-65868	A3 20001107	<--
			JP 2000-339853	A3 20001108	<--
			JP 2000-339905	A3 20001108	<--
			JP 2000-339949	A3 20001108	<--
			JP 2000-339957	A3 20001108	<--
			US 2000-708392	A3 20001108	<--

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal dysfunction, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an inhibitor of NEP (neutral endopeptidase; EC 3.4.24.11).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:338074 CAPLUS

DOCUMENT NUMBER: 134:336237

TITLE: Neuropeptide Y (NPY) antagonists for the treatment of female sexual dysfunction

INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 165 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097718	A1	20010509	EP 2000-309720	20001103 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

AT	285249	T	20050115	AT	2000-309722	20001103 <--
PT	1097719	T	20050429	PT	2000-309722	20001103 <--
ES	2233297	T3	20050616	ES	2000-309722	20001103 <--
ZA	2000006374	A	20020506	ZA	2000-6374	20001106 <--
ZA	2000006375	A	20020506	ZA	2000-6375	20001106 <--
ZA	2000006376	A	20020506	ZA	2000-6376	20001106 <--
ZA	2000006378	A	20020506	ZA	2000-6378	20001106 <--
AU	781186	B2	20050512	AU	2000-71411	20001106 <--
AU	781400	B2	20050519	AU	2000-71407	20001106 <--
AU	781403	B2	20050519	AU	2000-71408	20001106 <--
CA	2323183	A1	20010508	CA	2000-2323183	20001107 <--
CA	2323191	A1	20010508	CA	2000-2323191	20001107 <--
CA	2323464	A1	20010508	CA	2000-2323464	20001107 <--
CA	2324484	A1	20010508	CA	2000-2324484	20001107 <--
NO	2000005618	A	20010509	NO	2000-5618	20001107 <--
NO	2000005661	A	20010509	NO	2000-5661	20001107 <--
NO	2000005662	A	20010509	NO	2000-5662	20001107 <--
HU	2000004347	A2	20010628	HU	2000-4347	20001107 <--
HU	2000004348	A2	20010628	HU	2000-4348	20001107 <--
HU	2000004349	A2	20010628	HU	2000-4349	20001107 <--
HU	2000004350	A2	20010628	HU	2000-4350	20001107 <--
CN	1320426	A	20011107	CN	2000-137665	20001107 <--
CN	1322526	A	20011121	CN	2000-137671	20001107 <--
CN	1328824	A	20020102	CN	2000-137670	20001107 <--
NZ	508006	A	20020628	NZ	2000-508006	20001107 <--
NZ	508007	A	20020628	NZ	2000-508007	20001107 <--
NZ	508011	A	20020628	NZ	2000-508011	20001107 <--
NZ	508012	A	20020628	NZ	2000-508012	20001107 <--
BR	2000005266	A	20030408	BR	2000-5266	20001107 <--
CN	1575816	A	20050209	CN	2004-10071390	20001107 <--
CN	1636597	A	20050713	CN	2004-10085955	20001107 <--
JP	2001206855	A	20010731	JP	2000-339905	20001108 <--
JP	2001213802	A	20010807	JP	2000-339853	20001108 <--
JP	2001247478	A	20010911	JP	2000-339949	20001108 <--
JP	2001247479	A	20010911	JP	2000-339957	20001108 <--
BR	2000005276	A	20030408	BR	2000-5276	20001108 <--
BR	2000005299	A	20030415	BR	2000-5299	20001108 <--
US	6734186	B1	20040511	US	2000-708392	20001108 <--
US	20040254153	A1	20041216	US	2003-686390	20031015 <--
US	20050020547	A1	20050127	US	2003-686282	20031015 <--
US	20050070499	A1	20050331	US	2003-686349	20031015 <--
IN	2004DE00033	A	20070504	IN	2004-DE33	20040107 <--
KR	2004074021	A	20040821	KR	2004-50971	20040701 <--
KR	2004074022	A	20040821	KR	2004-50972	20040701 <--
KR	2004074023	A	20040821	KR	2004-50973	20040701 <--
JP	2005013237	A	20050120	JP	2004-268608	20040915 <--
JP	2005021167	A	20050127	JP	2004-267669	20040915 <--
JP	2005043377	A	20050217	JP	2004-269807	20040916 <--
JP	2005070055	A	20050317	JP	2004-269732	20040916 <--
AU	2005201482	A1	20050505	AU	2005-201482	20050407 <--
AU	2005202166	A1	20050616	AU	2005-202166	20050518 <--
AU	2005202750	A1	20050721	AU	2005-202750	20050623 <--
JP	2005350482	A	20051222	JP	2005-233224	20050811 <--

PRIORITY APPLN. INFO.:

GB	1999-26437	A	19991108 <--
GB	2000-4021	A	20000218 <--
GB	2000-13001	A	20000526 <--
GB	2000-16563	A	20000705 <--
GB	2000-17141	A	20000712 <--
US	2000-175161P	P	20000107 <--
US	2000-192962P	P	20000329 <--
US	2000-217479P	P	20000711 <--

```
                                                US 2000-221014P     P  20000727 <--
                                                US 2000-221093P     P  20000727 <--
                                                AU 2000-71408       A3 20001106 <--
                                                CN 2000-137670      A3 20001107 <--
                                                KR 2000-65740       A3 20001107 <--
                                                KR 2000-65863       A3 20001107 <--
                                                KR 2000-65868       A3 20001107 <--
                                                JP 2000-339853      A3 20001108 <--
                                                JP 2000-339905      A3 20001108 <--
                                                JP 2000-339949      A3 20001108 <--
                                                JP 2000-339957      A3 20001108 <--
                                                US 2000-708392      A3 20001108 <--
AB   A method of treating a female suffering from female sexual
     dysfunction, in particular female sexual arousal dysfunction, is
     described.  The method comprises delivering to the female an agent that is
     capable of potentiating cAMP in the sexual genitalia, wherein the agent is
     in an amount to cause potentiation of cAMP in the sexual genitalia of the
     female.  The agent may be admixed with a pharmaceutically acceptable
     carrier, diluent or excipient.  The agent is an antagonist of NPY.  Preparation
     of neutral endopeptidase inhibitors, also use for treating the above
     disorders, is also described.
REFERENCE COUNT:          8      THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
                                 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s arousal disorder
L8          910 AROUSAL DISORDER

=> s neuropeptide Y
L9        46771 NEUROPEPTIDE Y

=> s NPY
L10       29315 NPY

=> s L8 and L9
L11           6 L8 AND L9

=> dup rem L11
PROCESSING COMPLETED FOR L11
L12           6 DUP REM L11 (0 DUPLICATES REMOVED)

=> d 1-6 L12 ibib abs

L12  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:121066  CAPLUS
DOCUMENT NUMBER:          142:212370
TITLE:                    PDE10a inhibitors for treating diabetes and related
                          disorders
INVENTOR(S):              Sweet, Laurel
PATENT ASSIGNEE(S):       Bayer Pharmaceuticals Corporation, USA
SOURCE:                   PCT Int. Appl., 28 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    ---------------------  --------
     WO 2005012485        A2    20050210    WO 2004-US24073        20040727
     WO 2005012485        A3    20050414
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2534432	A1	20050210	CA 2004-2534432		20040727
EP 1651251	A2	20060503	EP 2004-779234		20040727
R: DE, ES, FR, GB, IT					
JP 2007508241	T	20070405	JP 2006-521981		20040727
US 20070032404	A1	20070208	US 2006-564680		20060113
PRIORITY APPLN. INFO.:			US 2003-491730P	P	20030731
			WO 2004-US24073	W	20040727

AB The methods of the invention relate to the treatment of diabetes, including type 2 diabetes, and related disorders by administration of a PDE10A inhibitor. Such PDE10A inhibitors may be administered in conjunction with alpha-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compds., β-3 agonist, or insulin. Such PDE10A inhibitors may also be administered in conjunction with body weight reducing agents. Further methods of the invention relate to stimulating insulin release from pancreatic cells, for example, in response to an elevation in blood glucose concentration, by administration of a PDE10A inhibitor.

L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:1035011 CAPLUS
DOCUMENT NUMBER:	142:33016
TITLE:	Neutral endopeptidase inhibitors for the treatment of female sexual dysfunction
INVENTOR(S):	Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S):	Pfizer Limited, UK; Pfizer Inc.
SOURCE:	Eur. Pat. Appl., 134 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1481667	A1	20041201	EP 2004-20972	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY, TR				
EP 1097719	A1	20010509	EP 2000-309722	20001103
EP 1097719	B1	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ES 2233297	T3	20050616	ES 2000-309722	20001103
ZA 2000006374	A	20020506	ZA 2000-6374	20001106
ZA 2000006375	A	20020506	ZA 2000-6375	20001106
ZA 2000006376	A	20020506	ZA 2000-6376	20001106
ZA 2000006378	A	20020506	ZA 2000-6378	20001106
CN 1575816	A	20050209	CN 2004-10071390	20001107
US 6734186	B1	20040511	US 2000-708392	20001108
US 20040254153	A1	20041216	US 2003-686390	20031015
US 20050020547	A1	20050127	US 2003-686282	20031015
US 20050070499	A1	20050331	US 2003-686349	20031015
IN 2004DE00033	A	20070504	IN 2004-DE33	20040107

KR 2004074021	A	20040821	KR 2004-50971		20040701
KR 2004074022	A	20040821	KR 2004-50972		20040701
KR 2004074023	A	20040821	KR 2004-50973		20040701
JP 2005013237	A	20050120	JP 2004-268608		20040915
JP 2005021167	A	20050127	JP 2004-267669		20040915
JP 2005043377	A	20050217	JP 2004-269807		20040916
JP 2005070055	A	20050317	JP 2004-269732		20040916
AU 2005201482	A1	20050505	AU 2005-201482		20050407
JP 2005350482	A	20051222	JP 2005-233224		20050811
PRIORITY APPLN. INFO.:			GB 1999-26437	A	19991108
			GB 2000-4021	A	20000218
			GB 2000-13001	A	20000526
			GB 2000-16563	A	20000705
			GB 2000-17141	A	20000712
			EP 2000-309722	A3	20001103
			US 2000-175161P	P	20000107
			US 2000-192962P	P	20000329
			US 2000-217479P	P	20000711
			US 2000-221014P	P	20000727
			US 2000-221093P	P	20000727
			AU 2000-71408	A3	20001106
			CN 2000-137670	A3	20001107
			KR 2000-65740	A3	20001107
			KR 2000-65863	A3	20001107
			KR 2000-65868	A3	20001107
			JP 2000-339853	A3	20001108
			JP 2000-339905	A3	20001108
			JP 2000-339949	A3	20001108
			JP 2000-339957	A3	20001108
			US 2000-708392	A3	20001108

GI



I

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal disorder, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an inhibitor of neutral endopeptidase. Preparation of selected compds., e.g. I, is included.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:5937 CAPLUS

DOCUMENT NUMBER: 138:73273

TITLE: Preparation of [1,2']bipyrazinyl 5-HT2 receptor ligands for treatment of sexual dysfunction

INVENTOR(S): Chiang, Yuan-Ching Phoebe; Dasilva-Jardine, Paul

Andrew; Garigipati, Ravi S.; Guzman-Perez, Angel; Novomisle, William Albert; Welch, Willard Mckowan

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000666	A1	20030103	WO 2002-IB2293	20020617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030105106	A1	20030605	US 2002-156884	20020528
US 6825198	B2	20041130		
US 20030125334	A1	20030703	US 2002-163881	20020605
US 6894050	B2	20050517		
CA 2455292	A1	20030103	CA 2002-2455292	20020617
AU 2002309183	A1	20030108	AU 2002-309183	20020617
NZ 529542	A	20031219	NZ 2002-529542	20020617
NZ 529543	A	20031219	NZ 2002-529543	20020617
EP 1401820	A1	20040331	EP 2002-735869	20020617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200400026	A	20040615	EE 2004-26	20020617
BR 2002010471	A	20040810	BR 2002-10471	20020617
HU 2004000251	A2	20040830	HU 2004-251	20020617
HU 2004000251	A3	20060228		
JP 2005501821	T	20050120	JP 2003-507071	20020617
CN 1630645	A	20050622	CN 2002-813734	20020617
CN 1745074	A	20060308	CN 2002-812554	20020617
ZA 2003008842	A	20041123	ZA 2003-8842	20031113
ZA 2003008843	A	20041123	ZA 2003-8843	20031113
IN 2003MN01057	A	20051021	IN 2003-MN1057	20031118
MX 2003PA11941	A	20040326	MX 2003-PA11941	20031218
BG 108491	A	20050131	BG 2003-108491	20031222
US 20050020604	A1	20050127	US 2004-922198	20040819
US 20050090503	A1	20050428	US 2004-922058	20040819
US 20050032809	A1	20050210	US 2004-942345	20040916
US 6995159	B2	20060207		
US 20050054656	A1	20050310	US 2004-942346	20040916

PRIORITY APPLN. INFO.:

US 2001-299953P	P	20010621
US 2002-156884	A3	20020528
US 2002-163881	A3	20020605
WO 2002-IB2293	W	20020617

OTHER SOURCE(S): MARPAT 138:73273

GI



I



II

AB Title compds. (I) [wherein X and Z = independently CR; R = H, halo, alkyl(amino), or amino; W = O, S, NH, alkylamino, or acetylamino; at least one of R1, R5, R6, or R7 = independently halo, NO2, (alkyl)amino, CN, CONH2, (halo)alkyl, or alkoxy; or C2R1R5 = 5- or 6-membered aromatic or fused ring; or R1 taken together with R2 or R8 forms a 5- or 6-membered fused ring; R2 and R8 = independently H or (cyclo)alkyl; n = 0-2; R3 and R9 = independently H, halo, alkyl, or alkyl substituted with OH, F, or alkoxy; R4 = H, OH, (hydroxy)alkyl, cyanoalkyl, alkylcarbonyl, alkoxy(carbonyl), or alkenyl; or N-oxides, prodrugs, pharmaceutically acceptable salts, solvates, or hydrates thereof] were prepared as 5-hydroxytryptamine (5-HT) receptor ligands, in particular 5-HT2C receptor ligands. For instance, 2,6-dichloropyrazine was coupled with piperazine-1-carboxylic acid tert-Bu ester using Na2CO3 in t-BuOH to give 6'-chloro-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic acid tert-Bu ester. Substitution with 3-chlorobenzyl alc. in the presence of KOH and 18-crown-6 in toluene followed by deesterification afforded 6'-(3-chlorobenzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl (II). Compds. of the invention demonstrated affinity at the serotonin 5HT2A and 5HT2C binding sites with Ki values ranging from 0.5 nM to 1.0 μM and 0.1 nM to 586.5 nM, resp. In a functional assay using 5-HT2C expressed NIH 3T3 cells, II displayed EC50 ≤ 1.0 μM. I and pharmaceutical compns. containing I are useful for the treatment of diseases linked to the activation of 5-HT2 receptors, such as sexual dysfunction (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:5934 CAPLUS
DOCUMENT NUMBER: 138:73272
TITLE: Preparation of piperazinylpyrimidines as 5-HT2 receptor ligands for treatment of sexual disorders
INVENTOR(S): Chiang, Yuan-ching Phoebe; Novomisle, William Albert; Welch, Willard Mckowan
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003000663		A1	20030103	WO 2002-IB2261	20020617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20030105106		A1	20030605	US 2002-156884	20020528
US 6825198		B2	20041130		
US 20030125334		A1	20030703	US 2002-163881	20020605
US 6894050		B2	20050517		
CA 2450491		A1	20030103	CA 2002-2450491	20020617
AU 2002309173		A1	20030108	AU 2002-309173	20020617
AU 2002309173		B2	20070426		
NZ 529542		A	20031219	NZ 2002-529542	20020617
NZ 529543		A	20031219	NZ 2002-529543	20020617
EP 1401819		A1	20040331	EP 2002-735853	20020617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002010503		A	20040518	BR 2002-10503	20020617
EE 200400025		A	20040615	EE 2004-25	20020617
HU 2004000249		A2	20040830	HU 2004-249	20020617
JP 2004534823		T	20041118	JP 2003-507068	20020617
CN 1630645		A	20050622	CN 2002-813734	20020617
ZA 2003008842		A	20041123	ZA 2003-8842	20031113
ZA 2003008843		A	20041123	ZA 2003-8843	20031113
IN 2003MN01071		A	20060106	IN 2003-MN1071	20031121
NO 2003005698		A	20040217	NO 2003-5698	20031219
BG 108495		A	20040831	BG 2003-108495	20031222
BG 108491		A	20050131	BG 2003-108491	20031222
US 20050020604		A1	20050127	US 2004-922198	20040819
US 20050090503		A1	20050428	US 2004-922058	20040819
US 20050032809		A1	20050210	US 2004-942345	20040916
US 6995159		B2	20060207		
US 20050054656		A1	20050310	US 2004-942346	20040916
PRIORITY APPLN. INFO.:				US 2001-299953P	P 20010621
				US 2002-156884	A3 20020528
				US 2002-163881	A3 20020605
				WO 2002-IB2261	W 20020617

OTHER SOURCE(S): MARPAT 138:73272
GI



I



II

AB Title compds. (I) [wherein X and Y = CR and Z = N; or Y and Z = CR and X = N; R = H, halo, alkyl(amino), or amino; W = O, S, NH, alkylamino, or acetylamino; at least one of R1, R5, R6, or R7 = independently halo, NO2, (alkyl)amino, CN, CONH2, (halo)alkyl, or alkoxy; or C2R1R5 = 5- or 6-membered aromatic or fused ring; or R1 taken together with R2 or R8 forms a 5- or 6-membered fused ring; R2 and R8 = independently H or (cyclo)alkyl; n = 0-2; R3 and R9 = independently H, halo, alkyl, or alkyl substituted with OH, F, or alkoxy; R4 = H, OH, (hydroxy)alkyl, cyanoalkyl, alkylcarbonyl, alkoxy(carbonyl), or alkenyl; or N-oxides, prodrugs, pharmaceutically acceptable salts, solvates, or hydrates thereof] were prepared as 5-hydroxytryptamine (5-HT) receptor ligands, in particular 5-HT2C receptor ligands. For example, 2,4-dichloropyrimidine was coupled with piperazine-1-carboxylic acid tert-Bu ester using Na2CO3 in EtOH to give 4-(2-chloropyrimidin-4-yl)piperazine-1-carboxylic acid tert-Bu ester. Substitution with 3,5-difluorobenzyl alc. using NaH in THF afforded 4-[2-(3,5-difluorobenzyloxy)pyrimidin-4-yl]piperazine-1-carboxylic acid tert-Bu ester. Deesterification followed by conversion to the salt produced II•xHCl. Compds. of the invention demonstrated affinity at the serotonin 5HT2A and 5HT2C binding sites with Ki values ranging from 0.5 nM to 625 nM and 0.2 nM to 238 nM, resp. In functional assays, II acted as a partial agonist using 5-HT2A and 5-HT2C expressed NIH 3T3 cells with EC50 values in the range of 0.16 μM to 7.6 μM and 0.016 μM to 7.0 μM, resp. I and pharmaceutical compns. containing I are useful for the treatment of diseases linked to the activation of 5-HT2 receptors, such as sexual dysfunction (no data).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:777881 CAPLUS

DOCUMENT NUMBER: 137:278918

TITLE: Preparation of cyclopentyl-substituted glutaric acid monoamides as neutral endopeptidase inhibitors for treating female sexual arousal disorder and related conditions

INVENTOR(S): Challenger, Stephen; Cook, Andrew Simon; Gillmore, Adam Thomas; Middleton, Donald Stuart; Pryde, David Cameron; Stobie, Alan

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079143	A1	20021010	WO 2002-IB807	20020318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030105132	A1	20030605	US 2002-96218	20020312
US 6660756	B2	20031209		
CA 2437113	A1	20021010	CA 2002-2437113	20020318
AU 2002241201	A1	20021015	AU 2002-241201	20020318
EP 1373192	A1	20040102	EP 2002-707042	20020318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300469	A	20040216	EE 2003-469	20020318
HU 2003003624	A2	20040301	HU 2003-3624	20020318
HU 2003003624	A3	20050628		
BR 2002008455	A	20040302	BR 2002-8455	20020318
CN 1492852	A	20040428	CN 2002-805409	20020318
JP 2004531505	T	20041014	JP 2002-577770	20020318
JP 4018545	B2	20071205		
NZ 527012	A	20050324	NZ 2002-527012	20020318
TW 254038	B	20060501	TW 2002-91105650	20020322
AP 1689	A	20061231	AP 2002-2467	20020328
W: BW, GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW				
IN 2003MN00704	A	20051111	IN 2003-MN704	20030716
MX 2003PA06597	A	20041015	MX 2003-PA6597	20030723
ZA 2003005721	A	20040726	ZA 2003-5721	20030724
BG 108130	A	20040730	BG 2003-108130	20030825
NO 2003004299	A	20031127	NO 2003-4299	20030926
US 20040106611	A1	20040603	US 2003-696021	20031028
US 6849649	B2	20050201		
HK 1060724	A1	20060818	HK 2004-103713	20040525
IN 2004MN00599	A	20050520	IN 2004-MN599	20041026

PRIORITY APPLN. INFO.:		
	GB 2001-7750	A 20010328
	GB 2001-13112	A 20010530
	GB 2001-20152	A 20010817
	US 2001-292485P	P 20010521
	US 2001-299031P	P 20010618
	US 2001-317777P	P 20010906
	US 2002-96218	A3 20020312
	WO 2002-IB807	W 20020318
	IN 2003-MN704	A3 20030716

OTHER SOURCE(S): MARPAT 137:278918
GI

I



II

AB The invention relates to cyclopentyl-substituted glutaric acid monoamides (shown as I; e.g. (2S)-2-[[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid), inhibition of neutral endopeptidase (NEP) enzyme, methods of preparation and uses, e.g. treating female sexual arousal disorder. In I, R1 is optionally substituted C1-6alkyl, carbocyclyl, heterocyclyl, H, C1-6alkoxy, amino, or sulfonylamino. X is the linkage -(CH2)n- or -(CH2)q-O- (wherein Y is attached to the O); wherein one or more H atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxyC1-3alkyl; C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or Ph groups; n is 3-7; and q is 2-6; and Y is optionally substituted Ph or pyridyl. One process for preparing I involves reacting II (Prot = protecting group) with Y-X-NH2 to give protected I, which is then deprotected and later optionally converted to a salt; other methods involve asym. hydrogenation of an alkene precursor to II. More than 100 example prepns. of intermediates and claimed compds. are included; most of the claimed compds. are N-phenpropyl amides. IC50 values against neutral endopeptidase and selectivity against neutral endopeptidase vs. ACE are given for some of the claimed compds.; for example, 3-[1-[[[3-(2,3-dihydrobenzofuran-5-yl)propyl]amino]carbonyl]cyclopentyl]propanoic acid showed an IC50 against NEP of 3 nM and a >300 selectivity against ACE. Test results for use of (2S)-2-[[1-[[[3-(4-chlorophenyl)propyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid in rabbit models of female sexual arousal response and male erectile response are included.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:391522 CAPLUS
DOCUMENT NUMBER: 136:395983
TITLE: Bombesin receptor antagonists, and combinations with other agents, for the treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
    WO 2002040008        A2    20020523    WO 2001-GB5018          20011114
    WO 2002040008        A3    20020822
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
            US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    WO 2002040022        A1    20020523    WO 2000-GB4380          20001117
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2429106           A1    20020523    CA 2001-2429106         20011114
    AU 2002023802        A     20020527    AU 2002-23802           20011114
    EP 1333824           A2    20030813    EP 2001-994552          20011114
    EP 1333824           B1    20050907
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    BR 2001015364        A     20030923    BR 2001-15364           20011114
    HU 2003001892        A2    20031128    HU 2003-1892            20011114
    HU 2003001892        A3    20050628
    JP 2004522710        T     20040729    JP 2002-542382          20011114
    NZ 525415            A     20041126    NZ 2001-525415          20011114
    AT 303804            T     20050915    AT 2001-994552          20011114
    MX 2003PA03482       A     20040910    MX 2003-PA3482          20030416
    US 20040087561       A1    20040506    US 2003-416934          20031204
PRIORITY APPLN. INFO.:                      WO 2000-GB4380       W  20001117
                                            GB 2001-9910         A  20010423
                                            GB 2001-11037        A  20010504
                                            WO 2001-GB5018       W  20011114

OTHER SOURCE(S):         MARPAT 136:395983
```

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V inhibitors, neutral endopeptidase inhibitors, and lasofoxifene. Preparation of compds. of the invention is described.

```
=> s L8 and L10
L13           0 L8 AND L10

=> file medline embase biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   175.87     176.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -29.60     -29.60

FILE 'MEDLINE' ENTERED AT 10:24:04 ON 03 SEP 2008
```

```
FILE 'EMBASE' ENTERED AT 10:24:04 ON 03 SEP 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:24:04 ON 03 SEP 2008
Copyright (c) 2008 The Thomson Corporation

=> s arousal disorder
L14        806 AROUSAL DISORDER

=> s neuropeptide Y
L15      35811 NEUROPEPTIDE Y

=> s L14 and L15
L16          0 L14 AND L15

=> s sexual dysfunction
L17      25545 SEXUAL DYSFUNCTION

=> s L15 and L17
L18         23 L15 AND L17

=> dup rem L18
PROCESSING COMPLETED FOR L18
L19          20 DUP REM L18 (3 DUPLICATES REMOVED)

=> s L19 and (AY<2003 or PRY<2003 or PY<2003)
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
   1 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
L20          9 L19 AND (AY<2003 OR PRY<2003 OR PY<2003)

=> d 1-9 L20 ibib abs

L20  ANSWER 1 OF 9     MEDLINE on STN
ACCESSION NUMBER:   2002428331     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 12184992
TITLE:              Disinhibition of female sexual behavior by a CRH receptor
                    antagonist in Syrian hamsters.
AUTHOR:             Jones Juli E; Pick Rebecca R; Davenport Matthew D; Keene
                    Alex C; Corp Eric S; Wade George N
CORPORATE SOURCE:   Center for Neuroendocrine Studies, University of
                    Massachusetts, Amherst, Massachusetts 01003, USA..
                    jones@cns.umass.edu
CONTRACT NUMBER:    DK-55829 (United States NIDDK)
                    MH-00321 (United States NIMH)
                    MH-20051 (United States NIMH)
                    NS-10873 (United States NINDS)
SOURCE:             American journal of physiology. Regulatory, integrative and
                    comparative physiology, (2002 Sep) Vol. 283, No.
                    3, pp. R591-7.
                    Journal code: 100901230. ISSN: 0363-6119.
PUB. COUNTRY:       United States
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
                    (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE:           English
FILE SEGMENT:       Priority Journals
ENTRY MONTH:        200209
```

ENTRY DATE: Entered STN: 20 Aug 2002
Last Updated on STN: 20 Sep 2002
Entered Medline: 19 Sep 2002

AB Several conditions that inhibit female sexual behavior are thought to be associated with altered corticotropin-releasing hormone (CRH) activity in the brain. The present experiments examined the hypothesis that endogenous CRH receptor signaling mediates the inhibition of estrous behavior by undernutrition and in other instances of sexual dysfunction. Intracerebroventricular (ICV) infusion of CRH or urocortin inhibited estrous behavior in ovariectomized steroid-primed hamsters. Conversely, ICV infusion of the CRH receptor antagonist astressin prevented the suppression of estrous behavior by food deprivation or by ICV administration of neuropeptide Y . Astressin treatment also induced sexual receptivity in nonresponders, animals that do not normally come into heat when treated with hormones, and this effect persisted in subsequent weekly tests in the absence of any further astressin treatment. Activation of the hypothalamo-pituitary-adrenocortical axis was neither necessary nor sufficient to inhibit estrous behavior, indicating that this phenomenon is due to other central actions of CRH receptor agonists. This is the first direct evidence that CRH receptor signaling may be a final common pathway by which undernutrition and other conditions inhibit female sexual behavior.

L20 ANSWER 2 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1995357007 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7630583
TITLE: Sexual function in altered physiological states: comparison of effects of hypertension, diabetes, hyperprolactinemia, and others to "normal" aging in male rats.
AUTHOR: Clark J T
CORPORATE SOURCE: Department of Physiology, Meharry Medical College, Nashville, TN 37208, USA.
CONTRACT NUMBER: GM-08037 (United States NIGMS)
HL-02482 (United States NHLBI)
RR-03032 (United States NCRR)
SOURCE: Neuroscience and biobehavioral reviews, (1995 Summer) Vol. 19, No. 2, pp. 279-302. Ref: 197
Journal code: 7806090. ISSN: 0149-7634.
PUB. COUNTRY: United States
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199509
ENTRY DATE: Entered STN: 21 Sep 1995
Last Updated on STN: 21 Sep 1995
Entered Medline: 7 Sep 1995

AB In this review, we examine the changes in sexual function that accompany deviations from "normal" physiological states. We propose that the changes one observes in many altered physiological states should not be viewed in isolation. We describe our paradigms for assessing sexual function, and proceed to evaluate how sexual function changes with hormonal deprivation and aging, in rat models for hypertension, in severe hyperprolactinemia, in streptozotocin-induced diabetes, after chronic alcohol intake, after chronic morphine administration, and after exposure to the heavy metal, cadmium. We will provide evidence for the involvement of adrenergic transmitters and two neuropeptides, neuropeptide Y and somatostatin, in the neuroendocrine regulation of sexual behavior. Finally, we compare and contrast the changes observed relative

to the changes seen in "normal" aging in rats. The sequence of age-related changes in sexual function is distinct. The first change observed is a decrement in ex copula erectile reflexes. Next are decreases in ejaculatory threshold, followed shortly by increases in initiation and reinitiation of copulation after ejaculation. This is followed by a decrement in the number of males copulating to ejaculation. Finally, there is a failure to initiate the copulatory process. This sequelae is relatively common, being evident after castration, with hyperprolactinemia, and after exposure to cadmium. The data available for sexual function in hypertension is incomplete and modified by the etiology, but a suggestion for this sequelae is seen in SHR. In contrast, sexual dysfunction associated with chronic morphine administration appears to be due to an initial deficit in motivational aspects. Testosterone reverses sexual dysfunction associated with castration, but not with idiopathic sexual inactivity, nor with sexual dysfunction associated with aging, diabetes, or chronic morphine administration. Comparing sexual function in rat models for hypertension, diabetes and chronic ethanol leads to the conclusion that increases in blood pressure, like decreases in testosterone, cannot be the primary causal factor for sexual dysfunction. Age, hormonal history of the subject, and the age at castration influence changes in sexual function. Age-related sexual dysfunction appears to be contributed to by changes in adrenergic-neuropeptidergic, to include sympathetic, systems. Site-specific administration of NPY induces alterations in parameters of copulatory behavior which mimic those seen in aging and the retention of ejaculatory behavior with aging is associated with site-selective attenuation (or reversal) of age-associated changes in NPY content. Yohimbine enhances copulatory activity in castrated and aging rats, and attenuates or reverses the antisexual effects of clonidine, epinephrine and somatostatin.(ABSTRACT TRUNCATED AT 400 WORDS)

ACCESSION NUMBER: 2002353675 EMBASE
TITLE: Functional continuum of regulatory peptides (RPs): Vector model of RP-effects representation.
AUTHOR: Koroleva, S.V. (correspondence); Ashmarin, I.P.
CORPORATE SOURCE: Department of Biology, Moscow State University, Vorobievy Gory, Moscow 119899, Russian Federation. kor-lana@mtu-net.ru
SOURCE: Journal of Theoretical Biology, (2002) Vol. 216, No. 3, pp. 257-271.
Refs: 126
ISSN: 0022-5193 CODEN: JTBIAP
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 17 Oct 2002
Last Updated on STN: 17 Oct 2002

AB During the past decades, bioactive (regulatory) peptides have been identified as the major players in the regulation of many important biological processes. Dozens of peptides have found their application as pharmaceutical agents, which further stimulated research in this field making it one of the most rapidly developing areas on the edge of biological science and medicine. However, the fast accumulation of enormous amounts of experimental data has revealed a great difficulty in their analysis and demanded the development of a systematic approach for

generalization of the obtained information. We propose a new computer-based algorithm for studying biological activities of regulatory peptides and their groups based on their representation as vectors in n-dimensional functional space. Our method allows the rapid analysis of databases containing thousands of polyfunctional regulatory peptides with overlapping spectra of physiological activity. The described method permits to perform several types of correlations which, when applied to the large databases, could reveal new important information about the system of regulatory peptides. It can select the groups of peptides with similar physiological role (peptide constellations) and search for the optimal peptide combinations with predetermined spectrum of effects and minimal side effects for their further pharmacological application. It can also reveal the role of regulatory peptides in induction of chain physiological reactions. .COPYRGT. 2002 Elsevier Science Ltd. All rights reserved.

L20 ANSWER 4 OF 9 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002308030 EMBASE
TITLE: Disinhibition of female sexual behavior by a CRH receptor antagonist in Syrian hamsters.
AUTHOR: Jones, Juli E. (correspondence); Pick, Rebecca R.; Davenport, Matthew D.; Keene, Alex C.; Corp, Eric S.; Wade, George N.
CORPORATE SOURCE: Center for Neuroendocrine Studies, Univ. of Massachusetts, 135 Hicks Way, Amherst, MA 01003, United States. jones@cns.umass.edu
SOURCE: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, (Sep 2002) Vol. 283, No. 3 52-3, pp. R591-R597.
Refs: 40
ISSN: 0363-6119 CODEN: AJPRDO
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 002 Physiology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 19 Sep 2002
Last Updated on STN: 19 Sep 2002

AB Several conditions that inhibit female sexual behavior are thought to be associated with altered corticotropin-releasing hormone (CRH) activity in the brain. The present experiments examined the hypothesis that endogenous CRH receptor signaling mediates the inhibition of estrous behavior by undernutrition and in other instances of sexual dysfunction. Intracerebroventricular (ICV) infusion of CRH or urocortin inhibited estrous behavior in ovariectomized steroid-primed hamsters. Conversely, ICV infusion of the CRH receptor antagonist astressin prevented the suppression of estrous behavior by food deprivation or by ICV administration of neuropeptide Y . Astressin treatment also induced sexual receptivity in non-responders, animals that do not normally come into heat when treated with hormones, and this effect persisted in subsequent weekly tests in the absence of any further astressin treatment. Activation of the hypothalamo-pituitary-adrenocortical axis was neither necessary nor sufficient to inhibit estrous behavior, indicating that this phenomenon is due to other central actions of CRH receptor agonists. This is the first direct evidence that CRH receptor signaling may be a final common pathway by which undernutrition and other conditions inhibit female sexual behavior.

L20 ANSWER 5 OF 9 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002220467 EMBASE

TITLE: News focus.
SOURCE: Current Drug Discovery, (2002) No. JUNE, pp. 13-16.
ISSN: 1472-7463 CODEN: CDDUAI
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
039 Pharmacy
006 Internal Medicine
LANGUAGE: English
ENTRY DATE: Entered STN: 11 Jul 2002
Last Updated on STN: 11 Jul 2002

L20 ANSWER 6 OF 9 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2002156783 EMBASE
TITLE: [Peptide receptors symposium - Montreal 2001: From gene to therapy].
Symposium sur les recepteurs des peptides - Montreal 2001: Du gene a la therapie.
AUTHOR: Regoli, Domenico; Quirion, Remi; Couture, Rejean
SOURCE: Canadian Journal of Physiology and Pharmacology, (2002) Vol. 80, No. 4, pp. i-ii.
ISSN: 0008-4212 CODEN: CJPPA3
COUNTRY: Canada
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical and Experimental Biochemistry
032 Psychiatry
037 Drug Literature Index
008 Neurology and Neurosurgery
LANGUAGE: English; French
ENTRY DATE: Entered STN: 16 May 2002
Last Updated on STN: 16 May 2002

L20 ANSWER 7 OF 9 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2001009795 EMBASE
TITLE: Melanocortin receptors: New opportunities in drug discovery.
AUTHOR: Wikberg, J.E.S. (correspondence)
CORPORATE SOURCE: Dept. of Pharmaceutical Biosciences, Division of Pharmacology, Uppsala University, Box 591 BMC, SE-751 24 Uppsala, Sweden. Jarl.Wikberg@farmbio.uu.se
SOURCE: Expert Opinion on Therapeutic Patents, (2001) Vol. 11, No. 1, pp. 61-76.
Refs: 43
ISSN: 1354-3776 CODEN: EOTPEG
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 003 Endocrinology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
039 Pharmacy
008 Neurology and Neurosurgery
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 19 Jan 2001
Last Updated on STN: 19 Jan 2001
AB The cloning of five different subtypes of melanocortin receptors, MC(1-5), have provided new opportunities for the discovery of drugs that may be useful for the treatment of a variety of clinically important conditions,

including MC(1) receptor agonists for inflammatory diseases, MC(3) receptor agonists for sexual dysfunctions and MC(4) receptor agonists and antagonists for treatment of obesity, anorexia and drug abuse. This review discusses patents covering the cloning of the MC receptors, the endogenous MC receptor antagonists agouti signalling peptide and agouti related protein and novel compounds target towards the MC receptors.

L20 ANSWER 8 OF 9 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1995146706 EMBASE
TITLE: Neuropeptide Y: A promising therapeutic target.
AUTHOR: Dhanoa, D.S. (correspondence)
CORPORATE SOURCE: Synaptic Pharmaceutical Corporation, 215 College Road, Paramus, NJ 07652 1410, United States.
SOURCE: Expert Opinion on Therapeutic Patents, (1995) Vol. 5, No. 5, pp. 391-396.
ISSN: 1354-3776 CODEN: EOTPEG
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
040 Drug Dependence, Alcohol Abuse and Alcoholism
037 Drug Literature Index
032 Psychiatry
030 Clinical and Experimental Pharmacology
002 Physiology
018 Cardiovascular Diseases and Cardiovascular Surgery
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 12 Jun 1995
Last Updated on STN: 12 Jun 1995

AB Neuropeptide Y is one of the most abundant and widely distributed peptides in both the central and peripheral nervous systems. It plays important physiological and pathophysiological roles in cardiovascular, eating and sleep disorders as well as depression, anxiety, pain, cocaine withdrawal and sexual dysfunction. Thus, it offers promising opportunities for therapeutic intervention. This article reviews the patent literature in the Neuropeptide Y area of drug discovery and assesses the therapeutic value of the latest pharmacological tools and agents.

L20 ANSWER 9 OF 9 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:144667 BIOSIS
DOCUMENT NUMBER: PREV200200144667
TITLE: Spiro compounds.
AUTHOR(S): Fukami, Takehiro [Inventor, Reprint author]; Kanatani, Akio [Inventor]; Ishihara, Akane [Inventor]; Ishii, Yasuyuki [Inventor]; Takahashi, Toshiyuki [Inventor]; Haga, Yuji [Inventor]; Sakamoto, Toshihiro [Inventor]; Itoh, Takahiro [Inventor]
CORPORATE SOURCE: Tsukuba, Japan
ASSIGNEE: Banyu Pharmaceutical Co., Ltd., Tokyo, Japan
PATENT INFORMATION: US 6335345 20020101
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Jan. 1, 2002) Vol. 1254, No. 1. http://www.uspto.gov/web/menu/patdata.html. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Feb 2002
Last Updated on STN: 26 Feb 2002

AB Spiro compounds of the general formula (I): ##STR1## wherein Ar1 represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents methine; Y represents an optionally substituted imino or oxygen atom. These novel spiro compounds exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.38	212.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-29.60

STN INTERNATIONAL LOGOFF AT 10:33:02 ON 03 SEP 2008